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Abstract
The development of tailored dosage forms provides a wide range 
of possibilities for meeting the needs of individual drug therapy. The 
personalized dosage forms improve the safety of drug treatment by decreasing 
the risk of overdosing and adverse reactions. Conventional drug preparations 
with fixed dose strengths are generally produced in large industrial scale. 
However, the tailored dosage forms for individual patients could be 
manufactured in small batches with specific materials, drug content and 
release profile. Therefore, alternative fabrication methods, such as printing 
technology, are being investigated for the customization of the dosage forms. 
Printing technology is a flexible method for the on-demand production of 
drug preparations with variable doses at the point-of-care.
The thesis was aimed at investigating the feasibility of two-dimensional 
(2D) printing technology for the fabrication of personalized dosage forms. In 
the 2D printed dosage forms, a pharmaceutical ink is typically deposited and 
solidified on a planar carrier substrate according to a predefined pattern. The 
dosing accuracy and reproducibility of the inkjet-printed formulations could 
be controlled on the single droplet scale. Furthermore, tailoring the properties 
and the composition of the formulations allows obtaining drug delivery 
systems (DDS) with controlled drug release profiles and/or with multiple 
active pharmaceutical ingredients (APIs). 
The versatility of 2D printing technology was demonstrated by preparing 
printed formulations either by inkjet or flexographic printing on planar 
edible substrates with different types of pharmaceutical inks. The printed 
formulations and their components were analyzed to allocate the crucial 
aspects in the development process and to improve the knowledge about the 
physicochemical properties, in vitro performance and stability of the printed 
APIs. The printability of the inks and the specific printing parameters were 
closely related to the rheological properties of the drug solutions. The solid 
state of the printed APIs was dependent on the ink composition, the ink 
incorporation capacity of the substrates, and the physicochemical properties 
of the APIs. Solid state analysis of the final dosage forms showed that the APIs 
were distributed uniformly in a crystalline or molecularly dispersed state. 
Furthermore, the flexographically prepared solid nanoparticulate systems 
exhibited an enhanced in vitro drug release due to the spatial distribution of 
the crystalline nanosuspension inks. 
The high dosing precision of the inkjet printing process was ensured by the 
stable jetting of the drug solutions. However, the dosing of nanosuspensions 
by flexographic imprinting was less accurate mainly because of the format 
of the ink transfer system. The dosing flexibility of the inkjet-printed 
pharmaceuticals could be regulated by adjusting the printing resolution 
or the physical size of the dosage units. Furthermore, the implementation 
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of non-destructive attenuated total reflectance Fourier transform infrared 
spectroscopy with multivariate data analysis showed high applicability for the 
quantification of printed pharmaceuticals. In addition to edible commercial 
substrates, the suitability of gelatin-based electrospun fiber matrices as 
carrier substrates for the fabrication of printed dosage forms was studied. 
Moreover, drug-loaded electrospun fiber mats were produced by stabilizing 
the amorphous state of a poorly water-soluble drug within the inner structure 
of these fibers. The use of drug-loaded fibrous substrates presented a unique 
approach for the preparation of dual DDS, where an API was inkjet-printed 
on the drug-loaded matrices that contained another API. The analysis of the 
designed combination DDS showed that both drugs exhibited an independent 
release behavior.
The thesis presents an extensive overview on the main aspects of the 
development of personalized dosage forms by 2D printing technology. The 
research improves the understanding of the key factors for successful tailoring 
and manufacturing of the printed dosage forms, elaborates on the quality 
control aspects of the printing process, and provides an insight into the 
essential properties and the performance of the printed pharmaceuticals.
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1. Introduction 
The significance of personalized medicine has increased tremendously 
over the last decades. The concept of individualized drug therapy defines 
that the patient-specific characteristics influencing the performance of 
pharmaceuticals are considered during the development of treatment. The 
flexible design of dosage forms could provide valuable advantages for the 
dosing of therapeutics according to the individual patient profile, reducing 
drug overdosing and adverse reactions, and increasing patient compliance. 
On the other hand, the need for such personalized dosage forms sets new 
requirements for the pharmaceutical manufacturing, since conventional 
production methods might not provide sufficient flexibility and cost-efficacy 
for the fabrication. 
Alternative methods, such as printing technology, are being investigated 
to provide precise tailoring of medicines. Due to the flexibility of this on-
demand manufacturing method, the daily dose adjustment could be easily 
accomplished. Furthermore, printing could be feasible for producing 
drug delivery systems (DDS) for controlled drug release and/or with 
multiple active pharmaceutical ingredients (APIs) at high accuracy and 
homogeneity already in low doses. Currently, both two-dimensional (2D) 
and three-dimensional (3D) printing technologies are being exploited in 
the pharmaceutics. The accuracy of 2D inkjet printing is provided by the 
drop-on-demand (DoD) technology that allows controlled deposition of 
pharmaceutical ink formulations in 2D pattern onto a carrier material. 
Typically, the solidification of the printed material is required to obtain solid 
dosage forms from 2D and 3D printing. The properties and therapeutic 
performance of the printed pharmaceuticals could be adjusted by modifying 
the individual components of the dosage forms. 
Despite its obvious advantages, the manufacturing specifications, 
requirement guidelines and applicable analytical techniques are needed for 
ensuring the final quality of the printed drug preparations. Due to the novelty 
of the production process, the analysis of the physicochemical properties 
of the formulations and the process-induced solid state transformations is 
needed. Currently, the pharmaceutical research is concentrating on defining 
the applicability and limitations of the production methods as well as the 
techniques for qualitative and quantitative analysis. 
The present research work focused on studying the applicability of 2D 
printing in the design and development of personalized dosage forms. 
The main objectives were to provide an insight into the tailoring of the 
printed dosage forms and to gain understanding about the physicochemical 
properties and behavior of the printed pharmaceuticals. 
Different drug formulations were prepared by inkjet printing on planar 
carrier substrates to define the dosing precision and the flexibility of the 
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printed pharmaceuticals in the solid dosage forms. The implementation 
of the attenuated total reflectance Fourier transform infrared (ATR-FTIR) 
spectroscopy was investigated for the quantitative quality control of printed 
formulations. Furthermore, solid nanoparticulate systems with poorly 
water-soluble APIs were prepared by flexographic printing with the aim of 
improving the drug release behavior of the drugs. Finally, the applicability of 
drug-loaded electrospun fiber matrices as carrier substrates was studied for 
the preparation of an inkjet-printed dual drug system. The overall hypothesis 
was that printing technology could be applied to prepare dosage forms with 
various APIs in low doses and combinations at high content uniformity, 
acceptable stability and favorable dissolution profile for individualized drug 
therapy.
Literature overview
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2. Literature overview 
2.1. Concept of personalized dosage forms 
The concept of personalized medicine is aimed at producing precisely 
tailored dosage forms for individualized drug therapy. The patient-specific 
requirements are defined based on various factors, including age, gender, 
race, weight, body composition, metabolic activity, genetics and lifestyle. 
This specific approach allows considering the unique factors that influence 
the pharmacokinetics and -dynamics of drugs, such as differences in drug 
therapeutic effect and adverse reactions (Cohen, 1999). The diagnostic tests 
for determining genetic variations and biomolecular pathways that affect 
the mechanisms of diseases are continuously developing. Therefore, the 
pharmaceutical manufacturers should provide possibilities for small-scale 
production for personalized dosage forms to meet the needs of these sub-
categories with specific characteristics (Hamburg and Collins, 2010). The 
flexibility in the manufacturing of personalized dosage forms could allow 
creating a continuous feedback loop between the clinical diagnostics and the 
optimization of the drug formulations (Alhnan et al., 2016; Sandler and Preis, 
2016). 
The preparation of age-appropriate medicines, especially for pediatric and 
geriatric drug therapy, need to follow some key aspects that help to ensure 
the suitable bioavailability, safety, dosing uniformity and administration 
acceptability (Breitkreutz and Boos, 2007; European Medicines Agency, 
2013). The route of administration and the suitable dosage forms are often 
determined by the bioavailability of the active compounds. The metabolic 
mechanisms of different age groups or concurrent diseases/therapies 
determine the absorption and the elimination of the drugs. Furthermore, in 
pediatric formulations, the use of safe excipients and additives is crucial to 
avoid any additional hypersensitivity reactions (Breitkreutz and Boos, 2007; 
European Medicines Agency, 2013). 
The choice of dosage forms influences the dose uniformity and the dosing 
scheme. Liquid or solid dosage forms can be acceptable depending on the 
stability of the formulation and/or accuracy of the dosing devices for multi-
dose containers and multiparticulate systems (Wening and Breitkreutz, 2011). 
Nevertheless, the patient acceptability and compliance is the main factor 
that ensures the regular intake of the medicines in practice. The palatable 
properties (size, shape, taste, smell, texture and appearance) of oral dosage 
forms determine the receptiveness of the formulations in pediatrics, geriatrics 
and patients with oral hypersensitivity reactions or swallowing problems 
(Wening and Breitkreutz, 2011). In addition, most of these properties are also 
crucial for topical dosage forms and affect their acceptability. In a nutshell, 
single-dose and ready-to-use dosage forms with easy-to-handle packaging 
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and explicit user instructions are highly preferred.  
By considering all the afore-mentioned requirements, the conventional 
dosage forms with a limited number of fixed drug doses have often 
shown to be too rigid or imprecise to meet the rapidly increasing needs 
of individualized drug therapy. When conventional dosage forms fail to 
provide acceptable flexibility for the personalization of the drug formulations, 
alternative manufacturing methods should be exploited already at the roots of 
pharmaceutical dosage form design to fill these requirements. 
Recently, a transportable manufacturing platform with a continuous 
production process from the synthesis to the final formulation was 
demonstrated (Adamo et al., 2016). The proof-of-concept system was 
presented to be suitable for the flexible preparation of essential liquid drug 
formulations in special emergency situations and/or remote locations 
as well as for the fabrication of rare medications in small quantities. The 
manufacturing of such a compact production unit shows that the possibility 
of having simple systems for on-demand fabrication of personalized dosage 
forms is far from impossible. Computationally controllable systems could 
be constructed for preparing dosage forms from materials that are already 
synthesized with a flexible dose adjustment and reliable in-line or on-line 
quality control. 
2.2. Two-dimensional printing technologies in pharmaceutics
Two (2D) and three (3D) dimensional printing techniques provide various 
possibilities to tackle the increasing demand for tailored drug delivery devices 
(DDD) and drug delivery systems (DDS), individualized dosing and drug 
combination therapies. Printing is relatively recent technological approach 
in pharmaceutics, although different contemporary printing techniques 
have been used in other fields for many decades. Pharmacoprinting is a 
manufacturing concept that includes the production of pharmaceutical 
products by means of printing technology. The research into the applicability 
of printing to produce DDS has steadily increased over the years (Katstra et 
al., 2000; Sandler et al., 2011; Alomari et al., 2015). Furthermore, printing of 
pharmaceuticals has also been exploited in drug discovery (Zhu et al., 2012), 
biomolecular and cell-based applications (Ihalainen et al., 2015), and the 
production of DDD (Wu et al., 1996; Tarcha et al., 2007). 
The general selection of suitable printing technologies can be made based 
on the relationship between the printing resolution and throughput. After 
which the feasibility of different printing methods is often dictated by the 
requirements for the final product and the properties of the materials. The 
2D printing technologies are generally divided into inkjet and roll-to-roll 
printing methods (Figure  1). An overview on the working principles and 
pharmaceutical applications of inkjet and flexographic printing will be given 
in more detail.
Literature overview
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Figure 1. Inkjet and roll-to-roll printing technologies. 
2.2.1. Inkjet printing 
The development of inkjet printing technology started in the middle of 
20th century. In general, inkjet printing is a non-contact method, where an 
ink is dispensed from an ink container through a printhead nozzle onto a 
predefined location on a substrate. The inkjet printing types are foremost 
based on the droplet formation mechanism in the printhead and divide into 
continuous and drop-on-demand (DoD) jetting technology. 
In the continuous inkjet systems, the ink is jetted out of the printhead 
continuously and single droplets are formed by electrical charge that breaks 
the jet into droplets that are deposited onto the substrate (charged) or 
deflected for recirculation (uncharged) (Figure  2A). Continuous printing 
finds use in industrial coding and labeling applications. 
In the systems based on the DoD technology, on the other hand, the 
ink droplets are ejected only when their deposition is needed for creating 
the printable image; therefore, no recirculation of the ink is necessary. This 
technique was developed to improve the reliability of the inkjet printing 
and to reduce problems caused by the ink charging and/or recirculation 
systems (Le, 1998). The commercially available inkjet printers that came to 
the market first in 1970s and 1980s are using thermal or piezoelectric DoD 
jetting (Le, 1998). The 2D printing systems for pharmacoprinting are mainly 
based on these techniques. However, other DoD methods, like solenoid valve 
and electrohydrodynamic (EHD) inkjet printing, have also been studied for 
pharmaceutical applications.
In solenoid valve inkjet printing, the droplet deposition is regulated by 
an electromagnetically controlled valve (Horsnell et al., 2009). The valve 
includes a ferromagnetic plunger that opens or closes the ink flow between 
the printhead ink chamber and nozzle when a magnetic field is generated by 
a surrounding coil that is activated/deactivated by an electrical current. This 
non-contact DoD technology allows printing single droplets with various 
sizes in nanoliter-scale. The printability of the inks and the geometry of 
the droplets are dependent on the ratio between the length and the orifice 
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diameter of the nozzle (Horsnell et al., 2009). Therefore, it is suitable for ink 
solutions and (nano)suspensions with a wide range of viscosity from 1 to 
400 mPa·s (Horsnell et al., 2009; Planchette et al., 2015). 
The EHD printing is an electrostatic inkjet method, where droplets are 
pulled out from the nozzle onto/into the substrate when the electrostatic 
forces of the system overcome the surface tension and the viscosity forces 
of the liquid (Elele et al., 2012). By tuning the settings of the EHD system, 
a suitable jetting mode is obtained for uniform droplet formation (Raje and 
Murmu, 2014). Other jetting modes, such as electro-spraying or -spinning, 
can be obtained at different configurations (Raje and Murmu, 2014). 
Besides the differences in the basic working principles of inkjet printers, 
the applicability of printing is dependent on the nozzle size and the substrate 
feeding setup or position. By default, the small size (approximately 30–500 pl) 
of ink droplets is one of the factors that ensures the high resolution and 
accuracy suitable for pharmacoprinting. 
2.2.1.1. Thermal inkjet printing 
The thermal inkjet (TIJ) printing uses an expansion-collapse principle of a 
vapor bubble for the droplet formation (Figure 2B). The vapor bubble forms 
on the surface of a heater located in the printhead either on the top (roof-
shooter) or on the side (side-shooter) of the nozzle. In addition, in 1980s 
Hewlett-Packard commercialized single-use printheads, allowing the disposal 
of the empty ink cartridges; thus, increasing the quality and reliability of the 
inkjet technology. 
TIJ printing is suitable for water-based inks that become highly heated (up 
to 300 °C) for about 2–10 µs during the vapor bubble formation and collapse. 
The uniformity of the droplet size and the speed of the printing are influenced 
by the refill of the ink chamber, that takes up to 200 µs depending on the ink 
properties, and the design of the printhead (Le, 1998). 
2.2.1.2. Piezoelectric inkjet printing 
In piezoelectric inkjet (PIJ) printing, the droplet formation is caused by 
the deformation of a piezo-ceramic material (Figure 2C–D). The sub-micron 
scale deformation of the piezo-element changes the volume of the ink in the 
chamber and produces a pressure wave that forces the ink to be ejected. For 
the droplet formation and expulsion, the produced acoustic wave needs to 
be sufficient to overcome the contradictory changes in the viscosity, surface 
tension and dynamic pressure (Le, 1998). The PIJ printing technologies are 
subcategorized into four modes – squeeze, bend, push and shear – based on 
the deformation mode of the piezo-element. Printers with a PIJ printhead are 
suitable for inks based on aqueous and non-aqueous solvents (de Gans et al., 
2004). 
In the shear-mode printheads, such as Spectra® PIJ printheads, a 
perpendicular relationship between the electrical field and the polarization 
Literature overview
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of the piezo element causes shear deformation of the piezo-ceramic plates for 
the ejection of the ink droplets (Figure 2D). For the droplet formation in the 
shear-mode printheads, the ink and the piezo-element are in direct contact. 
Figure 2. A: Continuous inkjet system with a binary deflection mode. B: 
Thermal inkjet system with a roof-shooter heating mode. C: Piezoelectric inkjet 
system with a bending deformation mode. D: Piezoelectric inkjet system with a 
shear deformation mode.
2.2.2. Roll-to-roll printing 
Roll-to-roll methods are mainly non-digital contact techniques that 
require physical transfer of the printing pattern onto the substrates. Typical 
roll-to-roll methods, including relief, gravure, (offset) lithography and 
xerography printing, have multiple industrial applications due to their 
high throughput capacity. However, the lower resolution of these methods 
is one of the limiting factors in the method selection for biomedical and 
pharmaceutical applications. Nevertheless, screen and (roto)gravure 
printing technologies have been successfully used for the fast deposition of 
biomolecules (Ihalainen et al., 2015). In pharmaceutics, the flexographic 
printing has shown limited applicability for the preparation of oral DDS 
(Genina et al., 2012; Janßen et al., 2013). 
2.2.2.1. Flexographic printing
Flexography is an imprinting method that is based on the concepts of 
relief printing, where ink transfer occurs by pressing or rubbing the substrate 
against a printing plate that has ink-covered relief surface (raised areas) with 
ink-free recessed areas.
The flexographic printing is typically a three-step process, where the 
system is built up from an anilox roll, doctor blade, patterned printing plate 
and an impression roll (Figure  3). The ink transfer from the anilox roll to 
the printing cylinder is controlled by the doctor blade. The small engraved 
cells on the surface of the anilox roll dictate the amount of the transferred 
ink. The printed area is formed by the relief pattern on the polymeric plate 
that covers the printing cylinder. Finally, the ink pattern is carried on to an 
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impression roll that is surfaced with the substrate. The printing quality is 
dependent on the individual properties of the ink and the substrates, the 
uniformity of the transferred ink layer and the connectivity between the 
printing plate and the substrate/impression roll (Kolakovic et al., 2013). 
Flexography is suitable for various ink formulations with non-volatile solvents 
that are stable at room temperature during the printing process. The printing 
speed and the robustness of flexography makes it a fruitful option for the on-
demand manufacturing of DDS; however, its lack of dosing precision has been 
recognized as one of the major challenges in the fabrication of solid dosage 
forms (Genina et al., 2012; Kolakovic et al., 2013).
Figure 3. Flexographic printing system.
2.3. Biomedical and pharmaceutical applications of printing 
Inkjet printing is typically used for home/office printing, graphic art or 
industrial/postal marking applications. However, the feasibility of 2D and 3D 
printing technologies in polymer light-emitting diode displays, electronics, 
ceramics, textiles, imaging and several biomedical applications is trending 
continuously (Le, 1998; de Gans, 2004). 
The quality and automated high throughput characteristics of inkjet 
printing have shown to be attractive for cost-effective biomedical and 
pharmaceutical applications. Besides 3D printing of DDD (Wu et al., 1998; 
Katstra et al., 2000; Shafiee and Atala, 2016), carrier-free 3D microstructures 
with predefined shapes can also be fabricated by inkjet printing (Yun et al., 
2009; Lee et al., 2012). 
Several reviews have been published on the inkjet and 3D printing of 
functional liquids or bioinks that contain biological materials, such as cells, 
extracellular matrices and bioactive macromolecules for tissue engineering 
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(Calvert, 2001; Zhu et al., 2012, Shafiee and Atala, 2016; Neves et al., 2016). 
The main practical challenges in the printing of proteins and cells are the 
biocompatibility between the materials and the printing system, and the 
suitable rheological properties of the liquids (Wilson and Boland, 2003; 
Derby, 2008). Due to the high shear rates in the printing systems, the 
optimization of bioinks is crucial to avoid the loss of biomaterial functionality 
(Di Risio and Yan, 2007; Derby, 2008). 
The precision, simplicity, robustness and rapid working speed of inkjet 
technologies provide cost-effective solutions in drug discovery (Lemmo et al., 
1998; Zhu et al., 2012; Scoutaris et al., 2016). In high throughput screening 
and microarrays, the inkjet deposition of reagents and assay compounds 
improves the screening processes for identifying new lead compounds 
or for discovering functional pathways and interactions in biological 
systems, respectively (Arrabito and Pignataro, 2000; Okamoto et al., 2000). 
Furthermore, inkjet printing is advantageous in the fabrication of simple and 
disposable biodevices (e.g., biosensors, biochips) for the detection of clinical 
analytes and biological samples (Zhu et al., 2012; Ihalainen et al., 2013, 2015). 
Due to the rapid development of inkjet-printed biomaterials, the lack of 
universal protocols and the intrinsic limitations of the inkjet principle have 
been identified as the main issues for its practical applications. 
2.3.1. Pharmaceutical applications of two-dimensional printing 
The applicability of inkjet printing in the production of solid DDS has 
been studied mainly for oral drug administration (Kolakovic et al., 2013; 
Alomari et al., 2015; Preis et al., 2015; Scoutaris et al., 2016). Besides that, 2D 
printing technologies have the potential to be exploited for preparing drug-
loaded microparticulate systems (Lee et al., 2012) or functional drug-loaded 
coatings for medical devices (Tarcha et al., 2007), transdermal microneedles 
(Boehm et al., 2014; Ross et al., 2015; Uddin et al., 2015) and implants 
(Nganga et al., 2014). The dose adjustment by pharmacoprinting has been 
noted to be a good alternative for liquid dosage forms or splitting of tablets 
(Alomari et al., 2015). 
The preparation of oral dosage forms by inkjet printing is beneficial for 
formulations containing APIs with low dose, narrow therapeutic index, 
rare therapeutic use and/or short-term stability. Due to the computationally 
controlled design and the simplicity of the production process, non-complex 
solid formulations can be prepared for personalized drug therapy. One 
of the proposed on-site manufacturing concepts includes providing the 
pharmacies or hospitals with pre-prepared inert substrates and drug-loaded 
ink containers that can be used for fabricating solid dosage forms in five 
steps: printing, drying, controlling, rolling and inserting into capsule (Voura 
et al., 2011). However, the capsulation of the printed materials is barely 
optional, since printed APIs on biocompatible carrier matrices can be directly 
administrated for enteral and/or transmucosal drug delivery. 
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The applications of inkjet printing/jetting have also been investigated 
and described for the preparation of oral or dermal DDS in pharmaceutical 
industry (Pickup et al., 2003; Figueroa and Ruiz, 2005). In addition, an 
industrial scale liquid dispensing technology (LDT) has been designed 
by GlaxoSmithKline (GlaxoSmithKline, n.d.). The LDT is a continuous 
manufacturing process, where water-soluble APIs in small doses (1–5 µg) are 
deposited on inert tablets with a subsequent drying, on-line near-infrared 
(NIR) imaging and coating process. 
In pharmacoprinting, flexography has been shown to be applicable for 
the deposition and solidification of (nano)suspensions that are problematic 
for inkjet printing due to nozzle clogging (Janßen et al., 2013; Raijada et al., 
2013; Malamatari et al., 2016). Compared to TIJ or PIJ printing, flexography 
allows depositing inks with higher viscosity (Genina et al., 2012; Raijada et al., 
2013). Flexography with verified dosing can provide possibilities for printing 
suspension inks with poorly water-soluble APIs and applying coating/barrier 
layers in advanced DDS. 
The oral DDS that have been prepared by 2D printing technologies on 
various biocompatible carrier matrices are presented in Table 1.
Table 1. Examples of oral dosage forms prepared by two-dimensional (2D) 
printing technologies. 
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2.3.2. Regulatory aspects of printed dosage forms 
The importance of personalized therapy has been recognized in terms 
of drug selection and dosing for the advanced prevention and treatment 
strategies based on the individual variability (Reidenberg, 2003; Woodcock, 
2007; Collins and Varmus, 2015). The precision medicine can be successfully 
implemented by combining therapeutics with diagnostic tests for the analysis 
of relevant biomarkers (Beaver et al., 2016). Therefore, the benefits of 
individualization depend greatly on the valuable information received from 
the diagnostic data that can be used to optimize the patient’s treatment. With 
the analytical advancements and the huge quantity of data, the focus lies in 
the quality and the interpretation of the received information (Woodcock, 
2007; Anaya et al., 2016). 
With the shift towards personalized medicine involving adjustable 
dosing and patient-specific drug combinations, the regulatory requirements 
are necessary to provide guidelines for the safety and quality control of the 
tailored dosage forms, as well as for the innovative manufacturing processes 
and devices. Thus, the development of printed DDS will be confronted with 
many challenges while future regulations on the evolving technologies for 
the fabrication of personalized dosage forms are worked out (Kolakovic et al., 
2013). 
The quantitative quality control and the sterility procedures of inkjet 
printing have been noted to be the key points for successful and safe drug 
dispensing at the point-of-care (Alomari et al., 2015). However, simple and 
applicable solutions for in-line monitoring of dosing are not yet developed. 
Currently available industrial methods are foremost for off-production testing 
and require regular cleaning (Daly et al., 2015). In addition, the occurrence 
of solid state transformations in pharmacoprinting must be addressed and 
controlled within the regulatory acceptance criteria (Daly et al., 2015). 
The advancements in the 3D printing technologies have led to an intense 
discussion by the regulatory parties on its applicability in practice (Di Prima 
et al., 2016). A clear differentiation between the industrially manufactured 
pharmaceutical preparations and magistral formulas could help to formulate 
the regulations around the printed medicines (Alhnan et al., 2016). In general, 
the production of drug preparations for individual patients and/or smaller 
patient groups is not beneficial for pharmaceutical companies. In that case, 
the importance of compounding facilities, e.g., pharmacies that prepare 
ex tempore preparations for patients, increases tremendously. However, 
currently these facilities are not regulated by the same laws as pharmaceutical 
manufacturing companies; thus, the safety guidelines for the compounding 
facilities should be revised with the increase of on-demand preparation of 
personalized medicines (Drues, 2013). 
The present regulatory requirements provided by the U.S. Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA) are 
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not adjusted for the manufacturing flexibility that is offered by the printing 
technologies (Alhnan et al., 2016). The un-resolved issues related to the 
process units, including the pharmaceutical ink formulation, the printer, 
the printing design and the printed drug preparations, have led to the need 
to modify the traditional regulations on pharmaceutics (Davies et al., 2015). 
However, despite the unconventional preparation approach, the solid dosage 
forms prepared by printing technologies must be manufactured according 
to the chemistry, manufacturing and control standards, including the 
International Conference on Harmonisation (ICH) Q10 Pharmaceutical 
Quality System guidelines, the International Organization for Standardization 
(ISO) quality standards and the good manufacturing practice (GMP) 
principles (International Conference on Harmonisation, 2008; Di Prima et al., 
2016; Goole and Amighi, 2016). 
The identification of critical process parameters by implementing Quality 
by Design (QbD) and Process Analytical Technology (PAT) tools could 
increase the conformity between new manufacturing methods and traditional 
regulatory evaluation systems (Goole and Amighi, 2016). The safety and 
efficacy issues for printed DDS raised by the authorities include mainly (1) 
the geometric features, porosity, mechanical properties and function of 
different materials; (2) the validation of manufacturing processes of individual 
production lines and quality assurance; (3) the evaluation and validation of 
parameters related to the patient matching and identification procedures; and 
(4) the cleanness of the instruments and the validation of the sterilization 
process (Food and Drug Administration, 2014; Di Prima, 2016). Furthermore, 
the applicability of these requirements and standards should be evaluated for 
non-traditional manufacturing sites (i.e., hospitals, clinics, pharmacies and 
academic centers) to avoid any unlawful adulteration to the printed DDS at 
the point-of-care (Davies et al., 2015; Sandler and Preis, 2016). Despite the 
recognition of the issues around pharmacoprinting, the evaluation of the 
critical aspects of printing technologies and the preparation of manufacturing 
guidelines will take time (Sparrow, 2014; Pollack and Coburn, 2015). 
So far, several 3D printed medical devices and implants without APIs 
have been approved through emergency use or expanded access pathways 
(i.e., as an investigational medical product that is accepted without prior 
clinical trials) (Davies et al., 2015; Alhnan et al., 2016). In addition, in 2015 
FDA approved the production of 3D printed Spritam® (levetiracetam) tablets 
for oral suspension in fixed formulations of four dose strengths (Aprecia, 
2015; Spritam, 2016). These 3D printed products have been cleared for use 
by providing at least an equivalent therapeutic performance compared to 
already marketed devices/products (Jacobson, 2015). All these achievements 
have been considered as significant steps towards the marketing of printed 
dosage forms with bioequivalent performance and further towards even more 
complex personalization of drug therapies. 
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Besides 3D printed tablets, the applicability of printing technology 
in the manufacturing of oral film formulations has been recognized 
(Preis et al., 2015). Recently, the European Pharmacopoeia's (Ph. Eur.) 
monograph on oromucosal preparations was expanded by two formulation 
types – mucoadhesive preparations and orodispersible films (European 
Pharmacopoeia, 2016a). However, the method specifications for the 
production guidelines and the analysis methods for the formulations, and the 
global harmonization of these regulations are still developing (Slavkova and 
Breitkreutz, 2014; European Pharmacopoeia, 2016a). 
The legal support of manufacturers, formulation designers and patients 
should be ensured by the clearly defined intellectual property rights, the 
tort liability issues, the reimbursement policies on the value of personalized 
medicines, and the authorization of shared design files (Davies et al., 2015; 
Alhnan et al., 2016; Beaver et al., 2016). Furthermore, the ethical, legal and 
regulatory basis for handling inter-subject pharmacokinetic differences 
(genetic factors and metabolic polymorphism) in clinical trials and the 
treatment prescriptions are not coherently defined yet (March et al., 2001; 
Lesko and Woodcock, 2002; Woodcock, 2007).
2.4. Design of printed dosage forms 
Developing therapeutically effective DDS with suitable performance 
profile (drug release and absorption) and verified quality is the foundation of 
any dosage form design. The structure of printed dosage forms is dependent 
on their administration route. Moreover, the patient compliance should be 
ensured by meeting the general requirements for size and shape of the dosage 
forms as well as for the organoleptic properties. Hereafter, the tailoring 
aspects of the printed dosage forms for oral (enteral, buccal, sublabial or 
sublingual) administration are described. 
The properties of the two main components of a typical printed system – 
ink and substrate – strongly influence the printing outcome. An optimized 
balance between the printability of the ink formulation, the physical 
properties of the substrate and the ink-substrate compatibility needs to be 
established to achieve final preparations with high quality. 
2.4.1. Ink formulations 
An optimized ink formulation is one of the key components of a 
successfully printed DDS. The inks can be divided generally into drug 
solutions (the most common type for inkjet printing), (nano)suspensions 
(Pardeike et al. 2011; Janßen et al., 2013; Cheow et al., 2014; Essel et al., 2014) 
and bio-functional inks (Di Risio and Yan, 2007; Derby, 2008; Borchers et 
al., 2011; Montenegro-Nicolini et al., 2016a, 2016b). Furthermore, inkjet 
printing can be applied for in situ formation of solid dispersions (Hsu et al., 
2012; Hirshfield et al., 2014), microcapsules (Yeo et al., 2003), co-crystals 
(Buanz et al., 2013) or co-amorphous systems (Wickström et al., 2015). 
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The properties of the solvent and the dissolved APIs, excipients and other 
additives determine the viscosity and surface tension of the ink, which are 
critical attributes for the ink printability. 
The dose of the printed API is directly influenced by its concentration in 
the inkbase solution. Water-based inks are preferred due to their non-toxic 
nature and suitability for TIJ and PIJ printing (Goodall et al., 2002; Buanz 
et al., 2011, 2015; Pardeike et al., 2011; Sandler et al., 2011; Genina et al., 
2012, 2013; Janßen et al., 2013; Cheow et al., 2015; Planchette et al., 2015; 
Vakili et al., 2016). In aqueous solutions, the concentration of water-soluble 
APIs can be easily modified to adjust the printed drug amount (Buanz et al., 
2011). However, many APIs possess certain limitations in solubility. Unlike 
TIJ printing, the PIJ printing is also applicable for inks with non-aqueous 
solvents, such as ethanol (Melendez et al., 2008; Scoutaris et al., 2011; Hsu et 
al., 2012; Janßen et al., 2013; Raijada et al., 2013; Hirshfield et al., 2014) or 
dimethyl sulfoxide (Wickström et al., 2015). However, the use of organic 
solvents should be limited, since it requires the removal of residual solvents 
after printing to avoid any toxic effects. In addition, solvents with low 
evaporation point might cause nozzle clogging and affect the printing quality. 
Hence, the ink concentration is highly dependent on the used solvent and/or 
the addition of solubilizing co-solvents (Di Risio and Yan, 2007; Kolakovic et 
al., 2013; Daly et al., 2015). The effect of various viscosity modifying agents, 
e.g., glycols, on the printability of enzymatic inks was tested by Di Risio 
and Yan (2007). Since then, humectants, such as glycerol (Melendez et al., 
2008; Buanz et al., 2011; Genina et al., 2012, Buanz et al., 2015; Vakili et al., 
2016), propylene glycol (PG) (Sandler et al., 2011; Genina et al., 2012, 2013; 
Wickström et al., 2016), polyethylene glycols (PEG) (Goodall et al., 2002; 
Elele et al., 2012; Raijada et al., 2013; Cheow et al., 2015) and hydroxypropyl 
cellulose (HPC) (Janßen et al., 2013) have been successfully added to various 
pharmaceutical ink formulations. Other ink components, including coloring 
and taste-masking agents, could be added to the formulation to obtain certain 
characteristics (Vakili et al., 2016; Wickström et al., 2016). 
On the other hand, the applied system defines the suitable properties of 
the ink solutions for the printing. Therefore, the final ink formulation is 
established based on the properties of the API and the requirements of the 
printing system. 
2.4.2. Substrates 
The manufacturing methods of carrier matrices that can be used as 
substrates for inkjet printing are very versatile. Polymer films that are 
typically used in orodispersible or mucoadhesive preparations are prepared 
by solvent casting or hot-melt extrusion. Edible porous icing sheets or starch-
based papers that are widely used in the food industry could also be feasible 
alternatives in the printed dosage forms. Ideally, generic substrates that are 
inert and compatible with a wide range of ink formulations and APIs are 
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preferred. On the other hand, the functionalization of the substrates provides 
additional properties, such as mucoadhesion, rapid disintegration or taste 
masking.  
The dosing capacity of the printed dosage forms is defined by the size and 
the fluid uptake capacity of the substrates. The administrable dimensions of 
oral films are 1–20 cm2 with an average size of 4–6 cm2 that is suitable for all 
age groups (Dixit and Puthli, 2009; Krampe et al., 2015). The dimensions of 
buccal DDS are generally smaller due to the limited application area (Krampe 
et al., 2015).
Considering the afore-mentioned limitations, the printing systems are 
generally suitable for APIs with low therapeutic dose (in a µg–mg range). 
The combination DDS with multiple potent APIs can be designed on a small 
printing area with defined drug deposition in separate compartments and/or 
by applying barrier coating layers (Scoutaris et al., 2011; Preis et al., 2015). 
2.4.2.1. Solvent casting of polymer films 
In solvent casting, thin films are produced by casting/spreading a 
homogeneous layer of a polymer solution on an inert surface. These polymer 
films are used in rapidly disintegrating orodispersible or prolonged-release 
buccal drug formulations (Dixit and Puthli, 2009; Hoffmann et al., 2011; 
Morales and McConville, 2011). 
The solution preparation, de-aeration, casting/molding, drying, cutting 
and packaging of the final dosage forms are the main six steps in the 
preparation of drug-containing films by solvent casting process (Hoffmann 
et al., 2011; Morales and McConville, 2011). Soluble additives and active 
compounds can be added to the film formulation in the solution preparation 
phase (Siemann, 2005). Whereas, the fabrication of polymer films with 
poorly soluble drugs in a suspension or emulsion has been known to cause 
precipitation or phase separation during drying. The solvent selection and 
the rheological properties of the solution determine the range of applicable 
APIs, toxicity (e.g., the presence of residual organic solvents), drying time, 
mechanical strength and stability of the films (Hoffmann et al., 2011). As an 
alternative to film casting, a solvent-free hot-melt extrusion method could 
be used to produce polymer films with thermostable materials under a heat-
controlled process (Hoffmann et al., 2011; Morales and McConville, 2011). 
The basic concepts on producing advanced DDS on oral films by inkjet 
printing for personalized drug therapy have been discussed by Preis et al. 
(2015). Inkjet printing of pharmaceuticals on quickly disintegrating, slowly 
eroding or permanent film substrates allows designing multi-component 
systems as mucoadhesive or orodispersible preparations for local or systemic 
drug delivery. Moreover, previous studies have demonstrated that flexography 
(Janßen et al., 2013) and inkjet printing (Buanz et al., 2015) showed no 
significant effect on the mechanical properties of the formulations printed 
on unloaded polymer films, whereas the incorporation of the API during 
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film preparation decreased the strength of the drug-loaded solvent-cast films 
compared to the unloaded films. 
2.4.2.2. Fibrous substrates by electrospinning 
During the electrospinning process, high an unidirectional electrical field 
is applied to the droplet of a polymer solution/melt to produce fine fibers / 
fibrous mats (Greiner and Wendorff, 2007; Agarwal et al., 2008; Bhardwaj 
and Kundu, 2010) (Figure  4). When the electrical forces overcome the 
forces of surface tension and charge, the fluid/melt forms a Taylor cone (i.e., 
a cone that forms at the tip of the capillary/needle where the liquid polymer 
jet is ejected during electrospinning or  spraying) (Taylor, 1964). This causes 
the deformation of the droplet and the ejection of a charged jet towards a 
grounded counter electrode (drum/plate collector). The solvent evaporates 
during the transfer of the solution from the ejector to the collector, and 
finally continuous solid fibers are collected on the grounded metal drum/
plate. Generally, non-woven fibrous scaffolds with random fiber alignment 
are produced due to the rapid whipping during the fiber formation. However, 
non woven mats with parallelly aligned fibers can be produced by applying 
suitable fiber collection methods (Liang et al., 2009).  
Figure 4. Electrospinning system. 
 Electrospinning is an easy-to-use but complex method, where the 
formation of fibers is highly dependent on the properties of the polymer(s) 
solution/melt and the parameters and conditions of the electrospinning 
process (Greiner and Wendorff, 2007; Bhardwaj and Kundu, 2010). Due 
to the adjustability of these attributes, it concurrently allows modifying 
and optimizing the properties of the fibers for versatile applications. For 
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example, the diameter, shape, surface topography and inner structure of 
the electrospun fibers are significantly influenced by the properties of the 
materials and the electrospinning solution/melt (e.g., molecular weight of the 
polymer, concentration, additives, viscosity, surface tension, conductivity), 
the process parameters (e.g., applied voltage, feed rate of the solution, the 
distance between the ejector tip and the collector), and the environmental 
conditions (humidity, temperature). Furthermore, the fiber morphology is 
dependent on the solvent properties, such as vapor pressure and boiling point, 
that determine the evaporation rate of the solvent(s) and the drying time. 
By optimizing the composition of the solution/melt and the electrospinning 
conditions, fibrous matrices with modified morphology and structure can be 
obtained.
The electrospun fibrous mats provide high biocompatibility in tissue 
engineering and local drug delivery due to their porous 3D structure that 
mimics the structure of the extracellular matrix (Agarwal et al., 2008). The 
fibrous matrices have large surface area to volume ratio and drug-loading 
capacity that is advantageous for developing DDS (Greiner and Wendorff, 
2007; Agarwal et al., 2008; Bhardwaj and Kundu, 2010; Hu et al., 2015). The 
electrospun fiber mats can be functionalized during the spinning process or 
via post-treatment (Liang et al., 2009). Furthermore, electrospinning is an 
attractive method from the industrial viewpoint due to the simplicity of the 
process and the possibility for large scale production. Nevertheless, the use 
of non-toxic solvents and ensuring the uniformity of the electrospun fibers 
remains challenging, and thus contributes to the limitations in the production 
(Agarwal et al., 2008; Schiffmann and Schauer, 2008; Bhardwaj and Kundu, 
2010; Hu et al., 2015).
Electrospun products are commercially available for various applications, 
such as filtration and textiles (Greiner and Wendorff, 2007; Bhardwaj and 
Kundu, 2010). Typical biomedical applications of electrospun fiber scaffolds 
are tissue engineering and drug delivery (Greiner and Wendorff, 2007; 
Agarwal et al., 2008; Bharwaj and Kundu 2010; Sridhar et al., 2011; Hu et al., 
2015). The adhesion/adsorption and proliferation of cells on the electrospun 
fibrous mats have led to their increased use in regenerative medicine. 
Electrospun fibrous systems provide advantageous possibilities for local 
drug delivery and controlled drug release. Fiber scaffolds containing APIs, 
such as antibacterial agents, anticancer drugs, growth factors and other 
bioactive molecules, for wound healing, chemotherapy or implants have been 
extensively investigated in the recent years (Agarwal et al., 2008; Sridhar et al., 
2011; Hu et al., 2015).
Electrospinning enables producing fibers with diameters in nano- 
to micrometer scale from natural (e.g., cellulose derivatives, chitosan, 
collagen, gelatin, elastin, silk protein) and synthetic (e.g., poly(lactic acid), 
polycaprolactone, copolymer poly (lactide-co-glycolide)) polymers, polymer 
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mixtures, non-polymeric materials and multi-component systems (Greiner 
and Wendorff, 2007; Schiffmann and Schauer, 2008; Liang et al., 2009; 
Bhardwaj and Kundu 2010). Furthermore, the post-treatment of electrospun 
fibers has shown to improve their mechanical strength and elasticity (Greiner 
and Wendorff, 2007). 
The porous matrices provide increased stability of metastable forms 
of drug molecules within the substrate structure and reduce the surface 
roughness of printed dosage forms (Sandler et al., 2011; Raijada et al., 2014). 
Therefore, the loosely fibrous structure of electrospun scaffolds shows high 
suitability for their use as substrates in inkjet printing.
2.5. Quality of printed dosage forms
The quality of the printed dosage forms is derived from three major 
aspects: ink printability, ink-substrate interactions and printing parameters. 
The optimization of the printing parameters allows fine-tuning of the printed 
DDS within the defined limits of the printing system. 
In PIJ printing, the droplet geometry and behavior can be optimized 
by adjusting the applied voltage, waveform (Liu et al., 2013), printing 
frequency and/or temperature. However, the effect of these parameters on 
the performance of pharmaceutical inks has not been systematically studied 
yet. The volume, velocity and trajectory angle of jetted droplets are directly 
influenced by the diameter of the nozzle (typically 30–60 µm). Generally, the 
ejection of smaller droplets enables to produce printable products at higher 
resolution. The definition of inkjet printing is limited by the diameter of the 
deposited droplet with a 1 pL droplet having a diameter of approximately 
12  µm (Derby, 2010). In that context, the main problem related to the 
inconsistency of the printing quality is nozzle clogging (Le, 1998; Calvert, 
2001). In comparison, the printing resolution of flexography is approximately 
30–75  µm (Kolakovic et al., 2013). The accuracy of the ink deposition is 
also determined by the substrate feeding system and the overall formulation 
design (e.g., printing pattern, resolution, layering).
2.5.1. Printability of ink formulations
The evaluation of the printability of an ink is based on its physical 
properties: viscosity, surface tension and density. These properties influence 
the droplet formation and the jetting stability (Le, 1998; Calvert, 2001). 
Viscosity is a dynamic parameter of a material that is defined as its 
resistance to flow and expressed as the rate of deformation (shear rate) against 
the applied stress (shear stress) at a constant temperature. Due to the small 
structures and applied forces, the shear rates involved in inkjet printing are 
about 105 s-1 (de Gans et al., 2004). This can lead to a non-linear flow behavior 
(i.e., shear thinning or  thickening); hence, the viscosity of the ink solutions 
must be controlled (Barnes et al., 1989). 
A phenomenon that describes the intermolecular forces between the liquid 
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molecules is called surface tension. Its value is defined by the force that is 
needed to increase the surface of a liquid by a unit area. For example, at room 
temperature the surface tension of water and ethanol is 73 and 23  mN/m, 
respectively. The optimal viscosity and surface tension for inkjet printing are 
in the range of 2–30 mPa∙s and 25–50 mN/m, respectively (Calvert, 2001; de 
Gans et al., 2004; Park and Moon, 2006; Di Risio and Yan, 2007; Jang et al., 
2009; Daly et al., 2015).  
Printability can be estimated by determining the Z-value of the fluid. The 
dimensionless Z-value (Equation 1) is an inverse of the Ohnesorge number 
(Oh), which is derived from the Reynolds (Re) and Weber (We) numbers 
(Fromm, 1984; McKinley and Renardy, 2011), where the ν, ρ, η, γ and a are 
defined as the average velocity, density, viscosity of the fluid and the radius of 
the printing nozzle. 
The Re and We numbers characterizes the fluid flow properties under 
viscous and capillary forces, respectively. Then again, the Z-value is 
independent of the fluid velocity or flow rate (Jang et al., 2009; McKinley 
and Renardy, 2011). The Z-value in a range from 1 to 14 has been described 
for printable inks (Jang et al., 2009; Derby, 2010). The schematic of the 
printability range is presented on Figure 5. 
Figure 5. Operational range of printable fluids for drop-on-demand inkjet 
printing, and photographic images of different ink droplets 140 ms after ejection 
from a single nozzle (Ø 50 µm) at a voltage of 25 V (Jang et al., 2009; McKinley 
and Renardy, 2011). Onset criterions for droplet formation and splashing have 
been given by Derby (2010). 
(Equation 1)
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In inkjet printing, the optimal viscosity and surface tension ensure the 
uniform formation of spherical droplets and the ink deposition by avoiding 
nozzle clogging or unwanted dripping of the ink (Calvert, 2001; de Gans et al., 
2004). By adjusting these parameters, the jetting of ink droplets without tails 
(Z  >  1) and without satellite droplets (Z  <  14) can be obtained. In aqueous 
inks, the printability is achieved by incorporating water-soluble/miscible 
solvent(s) as viscosity modifying agent(s) and/or surfactants. 
In the flexographic printing, the printability is foremost dependent on the 
viscosity of the ink. A uniform ink transfer onto a substrate can be achieved 
with viscous solutions or suspensions with values between 50–500  mPa∙s 
(Genina et al., 2012; Janßen et al., 2013; Kolakovic et al., 2013).
2.5.2. Ink-substrate interactions 
In the printed DDS, where the ink is deposited on a carrier matrix, the 
ink-substrate physical interactions affect the drying mechanism of the ink. 
These interactions can be categorized as the droplet spreading upon impact, 
the patterning on non-porous and porous substrates, and the droplet 
solidification (Derby, 2010). 
After a droplet is ejected from the printhead, the contact with the substrate 
is driven by the inertial impact and capillary forces (Derby, 2010). The contact 
angle of the droplets determines the droplet shape and the printed pattern 
caused by the merging of the droplets. Thus, the pattern of the solidified 
particles differs depending on the surface wettability and the hydrodynamic 
flows. Within the droplet these hydrodynamic flows, including the convective 
flow and the surface tension-based Maragoni flow, try to compensate for the 
solvent evaporation during drying (Park and Moon, 2006). A comprehensive 
overview by Park and Moon (2006) defined some of the underlying 
reasons for the differences in the inkjet-printed patterns on hydrophilic 
and hydrophobic surfaces by the deposition of ink formulations with silica 
microspheres in varied compositions and concentrations. 
The wettability of the substrate is affected by its roughness, surface energy 
and porosity (pore size, volume and geometry). A reduced ink spreading 
has been seen on porous substrates (Määttänen et al., 2010). However, on 
homogeneous non-porous materials the ink droplets tend to merge and form 
larger beads rather than to form a uniform layer (Calvert, 2001; Derby, 2010). 
On porous substrates, e.g., copy paper, the drying of water-based inks is 
dependent on the wettability of substrate surface (adsorption/spreading) 
and the ink penetration into the substrate (absorption/infiltration) with a 
concurrent evaporation of the solvent (Le, 1998; Määttänen et al., 2010). In 
the printed systems on impermeable substrates, the drying rate is determined 
mainly by the evaporation of the solvent (Le, 1998). The solidification process 
strongly dictates the ink distribution, and thus the shape and the pattern of 
the printed formulation. 
A homogeneous printing pattern is obtained by the sufficient solute 
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distribution during drying. The printing quality is diminished by the excessive 
and/or irregular spreading of ink droplets on the substrates (Le, 1998). Based 
on the adsorptive infiltration theory by Holman et al. (2002), the droplet 
localization can be controlled by increasing the ink affinity towards the 
substrate that causes the adsorptive confinement of the droplets to the surface. 
Layered systems are produced by printing several ink layers on top of 
each other with an intermediate drying step. The problems with smearing 
and erosion can be avoided by applying printing systems with stationary 
substrate holders, by separate solidification of the layers (e.g., by UV curing 
or thermal treatment) and/or by using porous substrates to increase the 
absorption capacity (Calvert, 2001). In DDS, the ink penetration into the 
porous substrates contributes to the high dosing precision (Genina et al., 
2013). When a solution is deposited on impermeable surfaces, the ink layers 
are merged due to the redissolution, resuspension or re-melting of the dried 
layers after depositing an additional layer (Calvert, 2001). 
Coated substrates provide additional flexibility for adjusting the 
characteristics of printing surfaces (Määtänen et al., 2010; Planchette et al., 
2016; Vakili et al., 2016). Vakili et al. (2016) noted that a hydrophilic coating 
on porous rice paper made the surface smoother, but also disintegrated/
dissolved after printing due to the ink incorporation into the surface layer. In 
addition, by adding backing and/or coating layers the drug release behavior 
can be modified (Voura et al., 2011; Genina et al., 2012; Preis et al., 2015). 
However, planar carrier substrates are not an obligatory part of DDS, since it 
is possible to use printing to produce drug-loaded coatings for DDD (Tarcha 
et al., 2007; Boehm et al., 2014; Nganga et al., 2014; Ross et al., 2015; Uddin et 
al., 2015) or to prepare independent drug-loaded microstructures (Lee et al., 
2012). 
Controlling the solid state characteristics of the printed solids is crucial 
in pharmaceutical formulations (Kolakovic et al., 2013; Daly et al., 2015). In 
the preparation of solid dosage forms, the properties of the substrates and the 
ink-substrate interactions influence the solidification and the crystallization 
of the printed APIs after solvent evaporation (Sandler et al., 2011; Hsu et al., 
2012; Raijada et al., 2013; Buanz et al., 2013).
2.6. Solid state properties of printed pharmaceuticals 
The identification of solid state forms of drugs and their stability within 
the dosage forms as well as the rate of the solid state transformations is a 
crucial part of the pharmaceutical product development. The ICH guidelines 
for new drug substances and drug products stipulate that the solid state 
(i.e., polymorphic, solvate/ hydrate or amorphous state) of APIs needs to be 
specified and controlled, when it is known to affect the biopharmaceutical 
performance of the drug product (International Conference on 
Harmonisation 1999a, 1999b). The pharmacoprinting process involves the 
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phase transformation of the API from a solution, suspension or emulsion into 
a solid state. For that reason, the crystallization behavior and the solid state 
properties of the printed pharmaceuticals need to be studied to control the 
performance of the DDS. 
2.6.1. Solid state forms 
Pharmaceutical materials that exhibit different solid state forms can 
exist as crystalline polymorphs, solvates/hydrates or in an amorphous state. 
Polymorphism is the ability of solid compounds to exist in more than one 
different crystalline phases (Haleblian and McCrone, 1969). The polymorphic 
materials have the same molecular composition, but a distinct structure 
due to the differences in the molecular arrangement in the crystalline 
lattice (Haleblian and McCrone, 1969; Byrn et al., 1994). The crystals of 
pharmaceutical compounds are connected with each other by physical non-
bonded interactions and/or by non-covalent hydrogen bonding (Byrn et al., 
1994). The physicochemical and thermodynamic properties and the stability 
vary between the solid state forms of APIs, and thus lead to modifications 
in their therapeutic performance (Haleblian and McCrone, 1969; Byrn et 
al., 1994). The presence of thermodynamically stable and/or metastable 
forms affects mainly the solubility, dissolution rate and consequently the 
bioavailability of the active compounds (Haleblian and McCrone, 1969). The 
stability of solutions or dispersions (suspensions, emulsions) is generally 
highly dependent on the initial polymorphic form of an API used for the 
preparation and on the solid state transformations occurring during storage 
(Haleblian and McCrone, 1969). In addition, it has been noted that the solid 
state form affects the chemical stability and the degradation rate of the drugs 
(Haleblian and McCrone, 1969; Hancock and Zografi, 1997). 
Solvates or hydrates are crystalline solids that contain solvent or water 
molecules within their crystal structure, respectively (Byrn et al., 1994; 
Vippagunta et al., 2001). Their properties, such as solubility, response 
to humid conditions and loss of solvent, vary from to their anhydrous 
counterparts as a consequent of different hydrogen bond patterns and crystal 
packing (Byrn et al., 1994; Vippagunta et al., 2001). The solvation/desolvation 
(or hydration/dehydration) phase transformations can cause instabilities in 
pharmaceutical systems and affect the bioavailability of drugs. For example, 
during drug release testing the formation of a hydrate within the solid dosage 
form can significantly affect the dissolution rate of an API (Aaltonen et al., 
2006). The solubility and dissolution rate of zwitter-ionic piroxicam (PRX) 
anhydrous and monohydrate forms were shown to have different aqueous 
solubility and dissolution behavior due to their distinct molecular structure 
(packing density, conformation, intra- and intermolecular bonding) and the 
degree of ionization in solutions with different pH values (Paaver et al., 2012).
Amorphous state is a unique non-crystalline state of solids, which has 
no 3D molecular order in long-range and the randomly arranged molecules 
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possess ordered structures only in short-range (Hancock and Zografi, 1997; 
Yu, 2001). The solids in an amorphous state are thermodynamically and 
chemically less stable, prone to moisture uptake and usually more soluble in 
water than in a crystalline state (Byrn et al., 1994; Hancock and Parks, 2000). 
Furthermore, small differences in the amorphous state can occur depending 
on the hydrogen bonding properties of the solid state form of the starting 
material (Savolainen et al., 2006). The formation and presence of amorphous 
solids influences its manufacturability, stability and biopharmaceutical 
performance (Hancock and Zografi, 1997). The amorphous state of materials 
can be obtained during vapor condensation, wet granulation, quench cooling 
of a melt, milling and compaction of crystals or precipitation from solutions 
by freeze- or spray-drying (Hancock and Zografi, 1997; Yu, 2001). However, 
amorphous solids can undergo crystallization at sufficient molecular mobility, 
upon exposure to heat and/or humidity (Yu, 2001).  
Solids in different polymorphic forms, amorphous state or as their 
mixture can be obtained intentionally or appear unintentionally during 
pharmaceutical processes. In the preparations containing drugs in amorphous 
or metastable forms, the systems need stabilizing in order to hinder the solid 
state transformations into thermodynamically most stable crystalline form 
(Haleblian and McCrone, 1969; International Conference on Harmonisation, 
1999a). The concentration of different polymorphs has a significant effect on 
the physiological availability of APIs mainly because of the variation in their 
absorption characteristics (Aguiar at al., 1967; Haleblian and McCrone, 1969).
2.6.2. Factors affecting solid state of printed pharmaceuticals 
Pharmaceutical materials, such as proteins, polymers and some sugars 
are commonly present in a fully or partially amorphous state (Yu, 2001). 
On the other hand, most APIs in amorphous state have higher energy levels 
compared to a thermodynamically stable crystalline (polymorphic) form 
and are inherently unstable. The bioavailability of APIs in Class I and III of 
Biopharmaceutics Classification System (BCS) is less likely to be impacted by 
the occurrence of polymorphism (Amidon et al., 1995). However, the solid 
state form of APIs belonging to the Class II (and Class IV) of BCS can affect 
their in vivo behavior due to the solubility-limited absorption (Amidon et al., 
1995). 
The preparation of multicomponent systems with stabilizing additives is 
one of the most common ways for stabilizing the amorphous state of drugs. 
The physical interactions between the components are mainly based on 
non-covalent hydrogen bonding, van der Waals forces (atomic repulsion/
attraction), electrostatic polar forces (dipole–dipole attraction), π–π or ionic 
interactions. In addition, the solid state form and water sorption properties 
of excipients affect the stability of pharmaceutical formulations. For example, 
Airaksinen et al. (2005) demonstrated that amorphous excipients hindered 
the hydrate formation from nitrofurantoin anhydrate during wet granulation, 
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whereas the crystalline excipients were unable to control the phase 
transformation. 
Phase transformations based on solution mechanism occur upon solvent 
removal/evaporation from solutions with entirely or partially dissolved drugs, 
for example, during wet granulation or spray-drying. Polymorphic transition, 
desolvation/dehydration, amorphous crystallization and vitrification are 
the main possible phase transitions during rapid solvent removal (Zhang et 
al., 2004). The solidification of drugs can result in a stable or unstable single 
phase or consist of a mixture of amorphous or crystalline solid state forms 
depending on the extent and rate of solvent removal and crystallization. 
The loss of crystallinity during printing process is influenced by the rapid 
evaporation of the solvent and the reduction of particle size (Vippagunta et 
al., 2001).  
The printed layer(s) on substrate can exhibit similarities with solid 
solutions or dispersions. Solid solutions are single phase systems consisting 
of multiple components. The dissolution rate of molecularly dispersed or 
dissolved drug(s) in these systems is determined by the carrier. Thus, the 
formation of solid solutions of poorly water-soluble drugs in aqueously 
soluble carriers is one way of increasing oral bioavailability. On the other 
hand, when the API is partially dispersed in the carrier material without any 
detectable crystallinity, multi-phase solid dispersions are obtained (Leuner 
and Dressman, 2000). 
The solidification of inkjet-printed pharmaceuticals is affected by the ink 
formulations, the substrate properties (roughness, porosity) and the ink-
substrate interactions. In exceptional cases, printing can be used to produce 
co-crystals (Buanz et al., 2013) or uniform nanoparticulate layers (Ihalainen 
et al., 2013), whereas DDS are generally obtained with well-distributed APIs 
in (micro)crystalline, molecularly dispersed and/or amorphous state. The 
type and the composition of the ink formulations affect the solid state of 
the API in the final preparations. For example, solubilizing agents, such 
as PG, are known to inhibit the crystallization of the dissolved API(s) and 
ease the dosing process (Scoutaris et al., 2011; Voura et al., 2011; Kolakovic 
et al. 2013). However, the solid state transformations with crystalline 
nanosuspension inks are unlikely, and their release behavior is mainly 
influenced by the particle size reduction and the extent of redispersion.  
2.7. Analytical methods for quality control of printed dosage 
forms 
In pharmaceutical manufacturing, the analysis of qualitative and 
quantitative attributes of the dosage forms can be conducted with several 
techniques in off-line, on-line or in-line measurement setups. Fast and non-
destructive methods that could be used for on-line or in-line quantification 
of active compounds, detecting and/or quantifying solid state transformations 
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are preferred. As part of the QbD approach, the implementation of PAT 
tools with multivariate data analysis allows achieving a continuous control 
and optimization of the manufacturing process. Besides the availability of 
instrumentation, acceptable detection and quantification limits must be 
assured for dose verification. 
Onsite fabrication of printed dosage forms can reduce the occurrence 
of solid state transformations and time-dependent physical or chemical 
degradation prior to drug administration (Raijada et al., 2013). However, the 
physical stabilization of amorphous APIs, e.g., by preparing hydrogen-bonded 
solid dispersions with polymers, might still be necessary (Serajuddin, 1999; 
Tantishaiyakul et al., 1999; Weuts et al., 2005, Lust et al., 2015). Nevertheless, 
monitoring the manufacturing process is crucial for controlling and detecting 
stability issues that can arise during the preparation of drug formulations.
The solid state characterization methods and their feasibility in qualitative 
and quantitative analysis of pharmaceutical solids have been investigated 
extensively over the last 50 years (Haleblian and McCrone, 1969; Hancock 
and Zografi, 1997; Newman and Byrn, 2003; Rodríguez-Spong et al., 2004; 
Zhang et al., 2004; Aaltonen et al., 2008, 2009; Chieng et al., 2011). For 
the quantification of active ingredients, conventional methods like high 
performance liquid chromatography (HPLC), ultraviolet-visible (UV-
Vis) spectrophotometry and mass spectrometry are still the mainly used 
techniques. However, non-destructive spectroscopic and diffraction methods 
that provide molecular information about the APIs have also been applied in 
the quantitative analysis. Many of these instrumentations can be integrated 
into the production line or used as handheld devices for fast quality control. 
Furthermore, continuously collected data can effectively be interpreted by 
multivariate data analysis. 
The X-ray diffraction (XRD) technique provides information in a 
particulate level about the crystallographic properties of materials and enables 
to differentiate between the polymorphic forms and the amorphous state of 
solids (Haleblian and McCrone, 1969; Hancock and Zografi, 1997, Chen et 
al., 2001; Vippagunta et al., 2001; Aaltonen et al., 2009; Chieng et al., 2011). 
For example, XRD together with chemometrics could detect solid-state 
transformations and the formation of amorphous PRX during ball-milling 
process (Kogermann et al., 2011). 
The vibrational spectroscopic methods – infrared (IR), NIR, Raman – have 
developed immensely over time and are used alone or in combination with 
other techniques and multivariate data analysis to detect and quantify solid 
state forms of pharmaceuticals (Savolainen et al., 2006; Aaltonen et al., 2008). 
Moreover, vibrational spectroscopy in combination with multivariate data 
analysis could be used for advanced qualitative and quantitative analysis of 
complex systems and/or controlling pharmaceutical processes (Auer et al., 
2003; Helmy et al., 2003; Boyer et al., 2006; Silva et al., 2009; Rajalahti and 
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Kvalheim, 2011; Mazurek and Szostak, 2012). 
The intramolecular vibrations in the structure of chemicals can be 
analyzed by IR spectroscopy. The IR spectroscopy allows detecting 
the absorption of the IR radiation caused by the changes in the dipole 
moment of the molecules. Thus, the obtained IR spectra allow identifying 
specific functional groups, presence of water and hydrogen bonding in 
pharmaceutical and other chemical compounds (Kalinkova, 1999; Auer 
et al., 2003). IR spectroscopy provides also valuable information on the 
intermolecular interactions, such as hydrogen bonding, between the drugs 
and the excipients (Kalinkova, 1999). Furthermore, the principle of attenuated 
total reflection (ATR) enables obtaining spectral information from the surface 
of the materials without any sample pretreatment (Figure  6) (Fahrenfort, 
1961; Offermann et al., 1995). 
 
Figure 6. Attenuated total reflectance (ATR) infrared spectroscopy. 
IR and Raman spectroscopy are generally complementary techniques for 
identifying the molecular structure and conformation of chemical entities 
(Halebian and McCrone, 1969; Byrn et al., 1994; Hancock and Zografi, 1997; 
Vippagunta et al., 2001; Christy and Egeberg, 2006; Aaltonen et al., 2009; 
Chieng et al., 2011). For example, Raman spectroscopy with chemometrics 
has been successfully used for the quantification of polymorphic mixtures 
of indomethacin (Heinz et al., 2007) and to observe amorphization of PRX 
during ball-milling (Kogermann et al., 2011).  
NIR spectroscopy, on the other hand, is less API-specific and provides 
valuable information on solid-water interactions (Aaltonen et al., 2009; 
Chieng et al., 2011). The in-line implementation of NIR or Raman 
spectroscopy with multivariate data analysis has allowed monitoring the 
hydrate formation from anhydrates (Jørgensen et al., 2002) or dehydration 
of APIs during drying process (Kogermann et al., 2008). Depending on the 
vibrational spectroscopy technique, the detection of compounds in low 
content has been shown to be limited by the method sensitivity towards 
the particle size of the solids and the homogeneity of the sample mixtures 
(Campbell Roberts et al., 2002; Heinz et al., 2007; Mazurek and Szostak, 
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2012).
So far, IR (Hammes et al., 2014; Offermann et al., 1995), NIR (Tumuluri et 
al., 2004) or Raman (Tumuluri et al., 2008; Zhang et al., 2014) spectroscopy 
in an off-line or in-line setup have been successfully used for drug content 
analysis of pharmaceutical film formulations. Research conducted by 
Melendez et al. (2008) was the first to apply Raman spectroscopy and XRD 
in the solid state characterization of printed pharmaceuticals. Later, Buanz et 
al. (2013) applied IR spectroscopy for detecting co-crystal formation during 
inkjet printing. 
Furthermore, hyperspectral imaging techniques that could be integrated 
into the manufacturing line are highly valuable for providing information 
about the drug distribution, surface chemistry and API content in the printed 
dosage forms. Recently, Vakili et al. (2014) showed that non-destructive NIR 
hyperspectral imaging combined with partial least squares (PLS) regression 
modelling was applicable for the API quantification in layered formulations 
(1–32 printed layers) prepared with a desktop inkjet printer. Furthermore, 
other high throughput imaging tools that have been applied for analyzing 
printed pharmaceuticals are time-of-flight secondary ion mass spectrometry 
(Scoutaris et al., 2012) and IR imaging (Chan and Kazarian, 2005). 
Another promising approach for quality control of printed 
pharmaceuticals is the use of handheld devices. In a combination with 
spectral libraries and multivariate data analysis, the handheld spectroscopic 
(Raman, mid-IR, NIR) devices show good acceptability for quality control 
applications (Sorak et al., 2012). To date, the use of Raman spectroscopy 
has shown to be limited by the excitation wavelength and the strength 
of Raman scattering and fluorescence (Sorak et al., 2012; Hajjou et al., 
2013). Additionally, a handheld colorimetry device was introduced for the 
quantification of printed pharmaceuticals. The incorporation of an edible 
color into the ink solutions allowed obtaining a correlation between the 
propranolol hydrochloride content and the color intensity in the printed 
layered formulations on three different edible substrates (up to 16 layers) 
(Vakili et al., 2015). On the other hand, it was shown that in a combination 
formulation when naturally colored active ingredients are added to the 
solution containing an edible color, the colorimetric analysis is limited by the 
color saturation at much lower number of printed layers (Wickström et al., 
2015). 
The hyperspectral imaging methods and the handheld devices are 
promising approaches for the quality control of dosage forms that are 
manufactured on-demand at the point-of-care. These techniques could 
be integrated into the printing device or used separately after the printing 
process, respectively. The main challenges that have arose are the detection 
and quantification limitations, the resolution of the measurements and their 
reliability in the analysis of drug combinations. The qualitative validation of 
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such devices for each DDS is necessary to avoid false results. 
Besides the quantitative analysis and the solid state characterization, 
tests that are related to the acceptability by the patient (mouth feel, taste and 
appearance), the stability and the mechanical strength during production, 
storage and handling are of importance in the development of oromucosal 
and/or topical dosage forms (Krampe et al., 2015). The structure of the 
manufacturing and quality control apparatuses must ensure minimal 
microbiological contamination and cross-contamination, for example by 
exploiting disposable ink cartridges and by using easily cleaned parts (tubing, 
printhead, probes etc.) that come into contact with the drug formulation. 
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3. Aims of the study 
The main goal of this research study was to investigate and gain 
understanding of the applicability of printing technology for the preparation 
of personalized dosage forms. The presented work aimed to design and 
characterize the printed dosage forms for patient-tailored drug therapy, and to 
establish the crucial attributes in the development process.
 
The specific objectives were to:
- Formulate the pharmaceutical inks, substrates and the dosage forms for 
inkjet and flexographic printing (I, III, IV)
- Characterize the physicochemical properties of the printed dosage 
forms (I-IV)
- Evaluate the dose accuracy and dosing flexibility of inkjet printing (I)
- Investigate the use of infrared (IR) spectroscopy in the quantification of 
printed dosage forms (II)
- Analyze the drug release behavior of solid nanoparticulate systems 
prepared by flexographic printing (III)
- Design and study the properties of a combination drug delivery system 
(DDS) with two active compounds (IV)
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4. Materials and methods 
The detailed descriptions of the materials and methods used for each 
research work are presented in the original publications (I–IV). 
4.1. Materials 
4.1.1. Active pharmaceutical ingredients 
The active pharmaceutical ingredients (APIs) used in the printed dosage 
forms are presented in Figure  7. The solutions for the inkjet printing 
contained caffeine (CAF) (Ph. Eur., Sigma-Aldrich, Germany) (I, II), 
loperamide hydrochloride (LOP) (Sigma-Aldrich, Italy) (I, II) and lidocaine 
hydrochloride (LH) monohydrate (≥99%, Sigma-Aldrich, India) (IV). 
Nanosuspensions with itraconazole (ITR) (Orion Pharma, Finland) and 
indomethacin (IND) (≥99%, Sigma–Aldrich, China) were prepared for 
flexographic printing (III). Piroxicam (PRX) in anhydrous form II (Letco 
Medical Inc., USA) was used as a poorly water-soluble model compound in 
the electrospun fiber substrates (IV). 
Figure  7. Chemical structures of caffeine (A), loperamide hydrochloride (B), 
itraconazole (C), indomethacin (D), lidocaine hydrochloride (E) monohydrate 
and piroxicam (F). 
4.1.2. Substrates 
Polyethylene terephthalate (PET) films (Mylar® A, Dupont Teijin Films 
Europe, Luxembourg) (I, II) and transparency films (TF) (DatalineTM, 
Esselte Office Products Oy, Finland) (III) were used as non-biocompatible 
reference substrates. Icing sheets (Sutton Valence, UK) (I), rice sheets 
(Easybake® edible rice paper, N.J. Products Ltd., UK) (III) and rice 
papers (Blue Dragon® Spring Roll Wrappers, UK) (III) were exploited as 
commercially available edible substrates. Solvent-cast hydroxyl propyl 
cellulose (HPC) (Klucel LF PHARM, Ashland, USA) films (I) and electrospun 
gelatin (Type A from porcine skin, Sigma-Aldrich, USA) substrates (IV) were 
prepared on a laboratory scale. 
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4.2. Methods 
4.2.1. Preparation of pharmaceutical inks 
Different inks were used for inkjet (I, II, IV) and flexographic (III) 
printing (Table  2). Propylene glycol (PG) (≥99.5%, Sigma-Aldrich, USA) 
acted as a viscosity modifying agent in the ink solutions (I, II, IV). A wet 
ball milling technique (Pulverisette 7 Premium, FritschCo., Germany) was 
used for the preparation of aqueous ITR and IND nanosuspensions (III). In 
the nanosuspensions a non-ionic surfactant Poloxamer 407 (Pluronic® F-127, 
BASF Co., Ludwigshafen, Germany) was exploited as a stabilizer. The solvents 
were purified water (Milli-Q) and ethanol (≥99.7%, Etax Aa, Altia OYj, 
Finland). 
Table 2. Composition of the pharmaceutical inks.
API Concentration Ink type Inkbase
I, II Caffeine (CAF) 20 mg/ml Solution PG and water in 30:70 (v/v) ratio
I, II Loperamide hydrochloride (LOP) 50 mg/ml Solution
PG and ethanol in 
40:60 (v/v) ratio
IV Lidocaine hydrochloride (LH) 330 mg/ml Solution
PG and water in 
40:60 (v/v) ratio
III Itraconazole (ITR) 112 mg/ml Nanosuspension
Poloxamer 407 (60% 
(w/w) of the drug 
amount) and water
III Indomethacin (IND) 145 mg/ml Nanosuspension
Poloxamer 407 (60% 
(w/w) of the drug 
amount) and water
API – active pharmaceutical ingredient; PG – propylene glycol
4.2.2. Preparation of solvent-cast substrates (I) 
The HPC films were prepared by solvent casting. A 5% (w/w) HPC 
aqueous solution was uniformly distributed onto a TF with 0.15 ml/cm2. The 
HPC films were dried at a temperature of 22  ±  2 °C and relative humidity 
(RH) of 45 ± 5% for 12 h.  
4.2.3. Preparation of electrospun substrates (IV) 
Electrospinning (ESR-200Rseries, eS-robot®, NanoNC, South Korea) 
was used to prepare fibrous gelatin substrates. Three different solutions 
for electrospinning were obtained by mixing the components at elevated 
temperatures (40–50  °C) (Table  3). An automatic syringe pump equipped 
with a syringe and a metallic syringe needle was used for continuous jetting of 
the solutions. For maintaining a steady solution temperature at 50 °C for G20 
and G20-PRX formulations, a melt electrospinning setup equipped with an oil 
circulator (NNC-OCB200, NanoNC, South Korea) was exploited. The specific 
parameters of the electrospinning for the preparation of different gelatin 
fibers are presented in Table 3. The fibrous gelatin substrates were crosslinked 
32
Materials and methods
through heat treatment after electrospinning. The theoretical concentration of 
PRX in the final drug-loaded gelatin substrate (G20-PRX) was 6.5% (w/w). 
Table 3. Composition of the electrospinning solutions and the parameters of 
electrospinning and crosslinking for the preparation of fibrous gelatin substrates.
G25a G20 G20‑PRX
Electrospinning solution
Gelatin concentration 25% (w/v) 20% (w/v)
Glucose concentration 3.75% (w/v) 3% (w/v)
PRX concentration - - 16 mg/mL
Solvent(s) 10 M acetic acid aqueous solution
10 M acetic acid aqueous solution 
and DMF in 1:4 (v/v) ratio
Electrospinning parameters
Pumping rate 8 µl/min 25–30 µl/min
Voltage 17–18 kV 14 kV
Distance between spinneret 
and collector ~14 cm ~18 cm
Solution temperature 25 ± 1 °C 50 °C
Crosslinking 
Heat treatment conditions 3 h at 170–175 °C 3 h at 130 °C
aFormulation by Siimon et al. (2014); PRX – piroxicam; DMF – dimethylformamide
4.2.4. Printing technology 
4.2.4.1. Piezoelectric inkjet printing (I, II, IV) 
A Dimatix DMP-2800 piezoelectric inkjet (PIJ) printer (Fujifilm Dimatix 
Inc., USA) with a typical droplet volume of approximately 10 pL was used for 
the printing of CAF and LOP inks (I, II). The printed dose of CAF and LOP 
on the substrates was varied by changing the printed area (cm2) or the drop 
spacing (DS) of the jetted droplets. Firstly, the effect of the printed area from 
0.4 to 4 cm2 on the dosing was studied with a step of 0.4 cm2 at a fixed DS of 
10 µm corresponding to a resolution of 2540 droplets per inch (dpi). Secondly, 
the flexibility of the dosing was investigated with increasing the printed 
dose by decreasing the DS of the printed ink from 50 µm (508 dpi) to 10 µm 
(2540  dpi) with a step size of 5  µm. The prepared samples were stored in a 
desiccator over silica granules (RH of 0–10%) at a temperature of 21 ± 1 °C. 
The printing of the LH ink solution was conducted with a PixDro LP50 
PIJ printer (Roth&Rau, The Netherlands) equipped with a Spectra® SL-128AA 
printhead (Fujifilm Dimatix Inc., USA) (IV). The formulations were printed 
with a resolution of 500 dpi on an area of 2 cm2 in two layers. A single nozzle 
at a voltage of 110 V was exploited to obtain droplets with an approximate size 
of 45–55 pL. The samples were dried for 2 h at 25 ± 1 °C before adding the 
second printed layer. All the printed dosage forms containing LH were stored 
at ambient conditions (temperature of 25  ±  1  °C and RH of 20  ±  2%) for a 
short-term stability study of 4 and/or 8 months. 
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The theoretical dose of APIs in the inkjet-printed formulations was 
calculated based on the droplet volume (pL), printing resolution (dpi), 
printed area (cm2), number of printed layers and ink concentration (mg/mL). 
4.2.4.2. Flexographic printing (III) 
The flexographically printed formulations were prepared by using a 
laboratory scale printability tester (IGT Global Standard Tester 2, IGT Testing 
system, The Netherlands). The ITR and IND inks were mixed for 15 min 
before the printing to ensure the homogeneity of the nanosuspensions. All the 
printed formulations consisted of 10 layers of the nanosuspension ink printed 
onto a sample area of 0.5 cm2. The dose of the deposited drug was determined 
only experimentally. 
4.2.5. Characterization of pharmaceutical inks (I, III) 
The viscosity of the CAF and LOP inkbase solutions was measured with a 
Physica MCR 300 rheometer (Anton Paar, Germany) in triplicate (I). A CAM 
200 contact angle goniometer (KSV Instruments Ltd., Finland) was used for 
measuring the surface tension of the inkbases by a pendant drop method in 
six parallel measurements and the contact angle of the CAF and LOP inks on 
the substrates by a sessile drop method in triplicate (I). 
The ITR and IND inks (III) for the flexographic printing were 
characterized with regards to the mean particle size and polydispersity index 
(PI) of the nanosuspensions by dynamic light scattering (Malvern Zetasizer 
Nano ZS, Malvern Instrument, Malvern, UK) in triplicate. 
4.2.6. Thickness of substrates (I, IV) 
AbsoluteTM Digimatic (Mitutoya Corporation, Japan) and Ironside® 
(France) digital calibers were used for measuring the thickness of edible (I) 
and electrospun (IV) substrates, respectively. For the mechanical testing, the 
dimensions of the electrospun samples were determined with the AbsoluteTM 
Digmatic digital caliper (Mitutoyo Corporation, Japan). 
4.6.7. Physical characterization of electrospun substrates (IV) 
The non-crosslinked (nonCL) and crosslinked (CL) electrospun gelatin 
substrates were characterized in terms of moisture uptake and mechanical 
properties (IV). The moisture uptake after exposing the substrates to 
high humidity (RH of 70%) was analyzed by a weighing method (APX-
200 balance, Denver Instrument, USA). The mechanical properties of the 
electrospun gelatin substrates before and after printing were studied by 
TA.XTplus Texture Analyzer (Stable Micro Systems Ltd., UK) equipped with a 
10 kg load cell (sensitivity of 0.001 N). All the measurements were carried out 
at ambient conditions (temperature of 25 ± 1 °C and RH of 20 ± 2%). 
In the puncture test, fixed samples with a circular sample area (Ø 10 mm) 
were punctured by a flat cylinder probe (Ø  5  mm) at a speed of 0.1  mm/s. 
The applied force (N) and displacement (mm) of the sample was used for 
the measurements of puncture strength (mN/mm2) and elongation (%) at 
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break. A tensile test with a speed of 0.1 mm/s was conducted to determine the 
tensile strength (N/mm2), elongation (%) at break and elastic modulus (kPa). 
Reference materials were copy paper (80 g/cm2, Staples Europe B.V., Finland) 
and 3-ply tissue paper (Kleenex®, Kimberly-Clark Worldwide Inc., UK).  
4.2.8. Scanning electron microscopy 
The surface morphology of the substrates and the printed formulations 
was visualized with LEO Gemini 1530 (Zeiss®, Germany) (I, III) and EVO MA 
15 (Zeiss®, Germany) (IV) scanning electron microscopes (SEM). In addition 
to surface visualization by SEM, an energy-dispersive X-ray spectroscopy 
(EDX) (Thermo Scientific, USA) extension was applied to detect the chemical 
elements of printed LOP (I). Furthermore, the diameter of the electrospun 
fibers was measured from the SEM images with ImageJ 1.49V software 
(National Institute of Health, USA) (IV).  
4.2.9. Thermal analysis 
The thermal properties of the printed CAF and LOP were studied by 
differential scanning calorimetry (DSC) (PYRIS Diamond, PerkinElmer 
Instruments, USA) (I). The printed CAF and LOP were detached from the 
PET substrate prior to the analysis, while the samples printed on HPC film 
and icing sheet remained attached to the substrates. 
A DSC (Q2000, TA Instruments, USA) with a conventional heating 
method and in a modulated temperature mode (MT-DSC) was used for the 
thermal analysis of the fibrous gelatin substrates and the printed formulations 
with LH (IV). All the measurements were conducted with intact samples (the 
printed LH remained attached to the substrate). 
In both studies a heating rate of 10 °C/min was applied in the conventional 
DSC mode, whereas in the MT-DSC measurements an average heating rate of 
3 °C/min with modulation amplitude of ± 1 °C over a period of 60 s was used. 
The DSC systems were calibrated with indium (156.60 °C). 
4.2.10. Solid state characterization 
4.2.10.1. X-ray diffraction 
The solid state characterization of the printed formulations was conducted 
by X-ray diffractometry (XRD) (Philips, X’Pert PRO MPD, The Netherlands) 
(I, II, III). The measurements were carried out in θ/2θ Bragg-Bretano 
geometry with Cu Kα radiation (l  =  1.54  Å) at a voltage of 40  kV and a 
current of 50  mA in the measuring range of 3–40°  2θ with the rate of 
0.04°/2 s. The solid state of the formulation compounds was evaluated based 
on the XRD diffractograms of the raw materials (I, III). 
A XRD (D8 Advance, Bruker AXS GmbH, Germany) equipped with 
a LynxEye one-dimensional detector (Bruker, Germany) was used for the 
analysis of the formulations printed on fibrous gelatin substrates (IV). 
A diffraction range from 3 to 55° 2θ with a step size of 0.02° 2θ and a total 
measuring time of 166 s/step at 40 kV and 40 mA was applied for measuring 
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the properties of the fibrous formulations. The International Centre for 
Diffraction Data PDF-2 database (2013 edition, USA) was used for the 
verification of the raw materials of LH monohydrate, PRX anhydrous form 
II and D-(+)-glucose. Experimental results from the samples containing 
PRX were compared with the theoretical patterns of PRX anhydrous form I 
(BIYSEH), anhydrous form II (BIYSEH02) and monohydrate (CIDYAP01) 
from the Cambridge Structural Database (UK), and PRX anhydrous form III 
(Naelapää et al., 2012) (IV). 
4.2.10.2. Attenuated total reflectance Fourier transform infrared 
spectroscopy (II, IV) 
An attenuated total reflectance Fourier transform infrared (ATR-FTIR) 
spectroscope (PerkinElmer, UK) equipped with a DiCompTM crystal was 
used for the spectroscopic analysis. The measurements were conducted in a 
spectral range from 400 to 4000 cm-1 with 4 accumulations and a resolution 
of 4 cm -1. A force of 150 N was applied during the analysis of the substrates 
and the printed formulations, whereas a force of 90–100  N was applied for 
the reference materials. Spectrum 10.03 software (PerkinElmer, UK) was 
used for the data collection and the pre-treatment of IR spectra with baseline 
correction and normalization. 
4.2.11. Quantitative analysis
The method selection for the content analysis of the drug-loaded samples 
was dependent on the API. The details of the analyses are described below. All 
the measurements were conducted at least in triplicate. 
4.2.11.1. Ultraviolet-visible spectrophotometry (I–III) 
The printed formulations of CAF (I, II) were measured at 206 and 273 nm 
by ultraviolet-visible (UV-Vis) spectrophotometry (Lambda 25, PerkinElmer, 
USA) after 12 h of incubation in water. 
The determination of IND (III) content in the nanosuspensions was 
performed by UV-Vis spectrophotometry (Ultrospec 2100 pro, Biochrom 
Ltd., UK) at 265 nm after 24 h of incubation in phosphate buffer (pH 5.0).
4.2.11.2. High performance liquid chromatography (I–IV) 
The printed formulations of LOP (I, II) were measured by high 
performance liquid chromatography (HPLC) with a modified method 
previously presented by Weuts et al. (2004). The LOP formulations were 
incubated in water for 12 h prior to analysis. A HPLC (Hewlett Packard Series 
II 1090 LC instrument) with Inertsil® ODS 3 column (4.0 × 150 mm, 5 µm) 
and a Security Guard Cartridge Kit (C18) (4.0 × 2.0 mm, 5 µm) was exploited 
to carry out an isocratic method at 40 °C with a 70:30 (v/v) mixture of 1 mM 
tetrabutylammonium hydrogensulfate aqueous solution and acetonitrile 
(ACN) as mobile phase. The flow rate of the mobile phase was 1.0  mL/min 
and the injection volume of the samples was 10  µL. LOP was detected at a 
retention time of 10 min at a wavelength of 220 nm.  
36
Materials and methods
The formulations with flexographically printed ITR nanosuspensions (III) 
were analyzed by HPLC (Agilent 1100 Series, Agilent Technologies, USA) 
equipped with a UV diode array detector and a Gemini-NX-C18 column 
(100  ×  4.6  mm, 3  µm) with a Security Guard Cartridge Kit (4.0  ×  3.0  mm, 
3  µm) (Phenomenex Inc., USA). An isocratic method at 25  °C was utilized 
with a 50:50 (v/v) mixture of 0.1% trifluoroacetic acid aqueous solution and 
ACN as mobile phase. The flow rate was 1.0 mL/min and the injection volume 
was 20  µL. The concentration of ITR was determined at a retention time of 
3.2 min at a detection wavelength of 261 nm.  
For the content analysis of the printed formulations with LH on unloaded 
or PRX loaded gelatin substrates (IV), a HPLC (Shimadzu Prominence 
LC20, Japan) equipped with a photodiode array detector and a Phenomenex 
Luna® C18(2) column (250  ×  4.6  mm) with base-deactivated end-capped 
octadecylsilyl gel for chromatography R (5  µm) as stationary phase was 
used. A HPLC method at 40  °C from the European Pharmacopoeia 
piroxicam monograph for the test for related substances was applied with 
minor modifications (European Pharmacopoeia, 2016e). The mobile phase 
was a 30:70 (v/v) mixture of ACN R1 and 6.81  g/L solution of potassium 
dihydrogen phosphate R previously adjusted to pH 3.0 with phosphoric acid 
R. The flow rate was 1.0  mL/min and the injection volume was 10  µl. The 
APIs were detected spectrophotometrically at a wavelength of 230  nm with 
an approximate retention time of 3.9  min and 22.0  min for LH and PRX, 
respectively. The LH formulations were analyzed after 6 h-incubation in water. 
The PRX content in the drug-loaded electrospun fibers was measured in 10 M 
acetic acid solution. The formulations with LH printed on CL PRX-loaded 
substrates (G20-PRX) were measured after in vitro enzymatic degradation 
by collagenase (235.00  units/mg, Glibco® Collagenase Type I isolated from 
Clostridium histolyicum, Life Technologies Corporation, USA) (Park et al., 
2002).
4.2.11.3. Spectral quantification (II) 
The IR spectra of the CAF and LOP formulations printed on PET 
reference substrate were subject to quantitative analysis. The original spectra 
were collected and pretreated with baseline correction, normalization and 
data tune-up processing in Spectrum 10.03 software (PerkinElmer, UK). 
Univariate and multivariate data analysis was conducted by preparing 
calibration models from two-thirds of the data and using one-third of the data 
to test the models. 
The univariate data analysis was conducted by plotting the height and 
area of API-specific absorbance bands against the resolution (expressed 
as DS) or the measured drug content. The models were evaluated based on 
their correlation coefficient (R2) and the root mean square error of prediction 
(RMSEP).
The multivariate data analysis was conducted with SIMCA-P+ 12.0.0.0 
Materials and methods
37
software (Umetrics AB, Sweden). Partial Least Squares (PLS) regression 
models (Wold et al., 2001) for quantification were prepared from the 
pretreated spectroscopic data. The API content was used in logarithmic scale 
for linear PLS regression models and recalculated for further analysis. Unit 
variance (UV) and mean centering (Ctr) scaling algorithms and Standard 
Normal Variate (SNV) pre-processing were applied to improve the quality 
of the data. Furthermore, the impact of the selected spectral regions, 400–
4000  cm-1 and 400–1750  cm-1, on the model performance was tested. The 
number of PLS latent variables (LVs) was set according to the cross-validation 
for auto-fitting (Eriksson et al., 2001) and verified by visual inspection. The 
quality of the PLS regression models was evaluated based on the correlation 
coefficients (R2X, R2Y), test set validation coefficient (Q2), root mean square 
error of estimation (RMSEE) and RMSEP. 
4.2.12. In vitro drug release studies (III, IV)
The drug release from the flexographically printed nanosuspensions of 
IND and ITR was studied by a modified dissolution testing method (III). 
A water bath was used to hold the temperature of the dissolution media at 
37  ±  0.5  °C. The printed samples in spiral capsule sinkers were immersed 
in 50  mL of dissolution media and a continuous mixing at 100  rpm was 
ensured by a magnetic stirrer. The samples were taken manually and analyzed 
by HPLC. Prior to the analysis, the samples were filtered through 0.2  µm 
polytetrafluoroethylene (PTFE) membrane syringe filters. The drug release 
from the printed IND formulations was determined in phosphate buffer 
(pH  5.0), whereas the dissolution rate of ITR formulations was studied in 
0.1 M hydrochloric acid solution (pH 1.2). 
A simulated saliva solution (pH  6.8) (Marques et al., 2011) was used 
to determine the drug release of PRX from nonCL and CL gelatin fibers 
and the dosage forms with printed LH on unloaded (G25) and PRX-loaded 
(G20-PRX) substrates (IV). The dissolution studies were conducted in 
Falcon tubes containing 10 mL of dissolution media. The Falcon tubes were 
inserted into water-filled paddle apparatus vessels for obtaining appropriate 
dissolution conditions (temperature of 37  ±  0.5  °C and a mixing speed of 
50 rpm). Separate samples were prepared for each time point and measured 
after manual sampling and filtering (0.45 μm PTFE membrane syringe filters) 
by HPLC. The dissolution studies were conducted under sink conditions in 
duplicate. 
38
Results and discussion
5. Results and discussion
5.1. Preparation and characterization of pharmaceutical inks 
and substrates for inkjet and flexographic printing (I, III, IV) 
5.1.1. Preparation and characterization of ink solutions (I, IV) 
The viscosity and surface tension are the most important physicochemical 
properties that affect the printability of an ink solution. The droplet formation 
and volume at a specific jetting voltage are directly influenced by these 
parameters (Jang et al., 2009). The ink performance quality outside the 
recommended viscosity and surface tension values is limited, and can lead 
to nozzle clogging, formation of satellite droplets and/or incomplete droplet 
ejection (Calvert, 2001; Jang et al., 2009).
In the preparation of drug-loaded inks, the solubility of the API in the 
solvent system (inkbase) and the evaporation rate of the solvent(s) must be 
considered. According to the solubility properties of APIs, an ethanol-based 
ink formulation was prepared with slightly water-soluble LOP and aqueous 
ink systems were obtained for CAF (sparingly soluble in water) and LH (very 
soluble in water) (European Pharmacopoeia, 2016b, 2016c, 2016d). 
The use of water or less toxic solvents, such as ethanol, acetone or dimethyl 
sulfoxide, is encouraged in pharmaceutical manufacturing (European 
Medicines Agency, 2016). However, these solvents are usually not appropriate 
for inkjet printing alone; thus, the addition of humectants, viscosity and/
or surface tension modifying agents is needed to ensure the printability 
of the ink formulations. Here, PG with a high boiling point (188  °C) was 
added to drug-loaded ink formulations to hinder the nozzle clogging and 
the crystallization of the solute by decreasing the evaporation rate of the 
inkbase. Despite of its benefits in the formulation, the administration of PG 
in high doses (above 25  mg/kg/day) and/or long-term should be monitored 
to avoid toxic effects especially in pediatrics and patients with renal or hepatic 
insufficiency (Lim et al., 2014). The PG content in all the printed formulations 
was well below the suggested limits. 
The printability of CAF and LOP inks was estimated based on the 
measured viscosity and surface tension (Table 4) (I). The calculated Z-value 
supported these findings. A stable jetting of both inks was obtained without 
any evident clogging. However, the differences in the surface tension 
influenced the droplet ejection resulting in the formation of satellite droplets 
or elongated droplet tails with CAF and LOP inks, respectively. 
The LH ink was prepared in a mixture of PG and water in 40:60 (v/v) 
ratio based on the preliminary analysis of the inkbase solutions (IV). The 
concentration of PG correlated linearly with the physicochemical properties 
of the inkbase solutions and the Z-value. A stable droplet formation was 
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maintained throughout the printing process of the LH ink. It was noted that 
the range of printable inks depends on the printhead configuration (nozzle 
diameter), and the droplet formation process could be adjusted by the settings 
of the printing process.
Table  4. Physicochemical properties and calculated Z-value for the ink 
formulations with caffeine (CAF) and loperamide hydrochloride (LOP).
Viscositya (mPa·s) Surface tension
b 
(mN/m)
Average Z‑value 
(nozzle Ø 21.5 µm)
CAF ink 2.6 ± 0.1 50.7 ± 1.0 12.8
LOP ink 3.6 ± 0.2 25.7 ± 0.7 6.9
amean ± standard deviation, n = 3; bmean ± standard deviation, n = 6.
5.1.2. Preparation and characterization of nanosuspensions (III)
The preparation of nanosuspensions is a common method to enhance 
the dissolution rate and absorption of solubility-limited APIs. The 
nanosuspensions with particles in sub-micron size range were prepared with 
BCS Class II model compounds, IND and ITR (Amidon et al., 1995). 
In the wet ball-milling process, the particle size of the solids was decreased 
by mechanical grinding with milling pearls in an aqueous environment 
in the presence of a stabilizing polymer. Maintaining the particle size of 
nanosuspensions in long-term is the main challenge, because of the higher 
surface energy of the nanoparticles that promotes their aggregation into 
thermodynamically stable state (Merisko-Liversidge and Liversidge, 2008). 
Typically freeze- or spray-drying of nanosuspensions has been exploited 
to stabilize these systems (Lee, 2003; Van Eerdenbrugh et al., 2008a; Chung 
et al., 2012; Figueroa and Bose, 2013). Moreover, the preparation of solid 
redispersible nanoparticulate systems by inkjet micro-dose dispensing 
(Pardeike et al., 2011) and flexographic printing (Janßen et al., 2013) has been 
shown to be a fitting alternative. The even spatial distribution of particles by 
printing could enhance the redispersion of the particles in the dissolution 
medium. 
The ITR and IND inks were prepared with typical particle size and 
distribution for ball-milled nanocrystalline suspensions (Table  5). The 
differences in the average particle size were attributed to the stabilizing 
efficiency of non-ionic Poloxamer 407, since the drug-polymer interactions 
are affected by the hydrophobicity and ionization degree of the API molecules 
(Liu et al., 2011). 
Table 5. Mean particle size and polydispersity index (PI) of itraconazole (ITR) 
and indomethacin (IND) nanosuspension inks. 
Particle sizea (nm) PIa
ITR ink 698.1 ± 14.0 0.37 ± 0.03
IND ink 422.6 ± 7.7 0.31 ± 0.01
amean ± standard deviation, n = 3.
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5.1.3. Characterization of electrospun substrates (IV) 
5.1.3.1. Fiber diameter 
The G25 and G20 gelatin fibers with different fiber diameters were 
produced by electrospinning (Table  6). The higher viscosity of the G20 
electrospinning solutions contributed to the increased diameter of the 
fibers. The G25 and G20 fibrous substrates were prepared with a thickness of 
0.05 ± 0.02 and 0.06 ± 0.02 mm, respectively. 
The thermal post-treatment did not affect the average diameter of G25 
fibers, whereas the diameter of G20 decreased by 8.6%. This phenomenon 
was attributed to the higher solvent residue in the G20 fibers that evaporated 
during crosslinking at elevated temperature (Bhardwaj and Kundu, 2010). 
5.1.3.2. Mechanical properties
Various crosslinking methods have been reported to improve the 
mechanical strength of electrospun gelatin fibers and films (Zhang et al., 
2006; Nguyen and Lee, 2010; Zha et al., 2012; Siimon et al., 2015). The 
physical properties of the electrospun gelatin substrates showed up to 5-fold 
enhancement after thermal crosslinking and the calculated elastic modulus 
demonstrated that the flexibility of the substrates was significantly increased 
after the heat treatment (Table  6). The higher mechanical strength of the 
CL G25 gelatin substrate formulation led to its use in the preparation of the 
inkjet-printed dosage forms.
Table  6. Average fiber diameter and physical properties of non-crosslinked 
(nonCL) and crosslinked (CL) G25 and G20 gelatin substrates, and reference 
materials.
Fiber 
diametera
(nm)
Puncture testb Tensile testb
Burst 
strength
(mN/mm2)
Elongation 
at break (%)
Tensile 
strength
(N/mm2)
Elongation 
at break (%)
Elastic 
modulus 
(kPa)
G25 substrate
nonCL G25 589.3 ± 70.1 32.3 ± 3.6 1.1 ± 0.1 4.4 ± 0.4 1.2 ± 0.4 48.6 ± 7.7
CL G25 607.8 ± 79.2 203.7 ± 6.4 6.6 ± 0.8 6.1 ± 0.7 8.1 ± 2.3 9.8 ± 0.7
G20 substrate
nonCL G20 1292.9 ± 231.2 79.0 ± 16.2 1.4 ± 0.2 2.3 ± 0.7 1.1 ± 0.4 24.7 ± 3.1
CL 20 1186.3 ± 225.7 95.8 ± 22.2 2.3 ± 0.5 2.8 ± 0.6 2.7 ± 0.3 6.5 ± 1.1
Reference materials
Copy paper - 1685.8 ± 75.0 6.3 ± 0.4 50.0 ± 5.4 5.6 ± 0.8 86.5 ± 6.6
3-ply tissue - 137.5 ± 11.2 23.4 ± 6.9 2.5 ± 0.1 1.2 ± 0.1 1.1 ± 0.1
amean ± standard deviation, n = 100. bmean ± standard deviation, n = 3–5.
5.1.3.3. Solid state properties 
The effect of the electrospinning and subsequent crosslinking on the solid 
state properties of gelatin was evaluated by thermal and IR spectral analysis. 
The physical properties of the substrates were influenced by the changes in the 
gelatin structure that occurred during the preparation process. 
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The characteristic endotherm that was attributed to the water evaporation 
with an overlapping denaturation of gelatin (107 °C) decreased approximately 
30  °C after electrospinning (Figure  8A). However, the stability of gelatin 
fibers was not affected by thermal crosslinking. Contradictory results have 
been obtained by the post-treatment with glutaraldehyde, showing an 
increased thermal stability of fibers (Zhang et al., 2006; Nguyen and Lee, 
2010). After crosslinking the melting endotherm (at 149–160  °C) of glucose 
disappeared (Figure  8A), suggesting that the thermal properties of gelatin 
fibers were stabilized by a reaction between glucose and gelatin at high 
temperature. 
The electrospinning and crosslinking processes affected the intramolecular 
vibrations of the fiber components. The absorbance bands of gelatin amide 
groups at 1234, 1524 and 1634 cm-1 were shifted to higher wavenumbers after 
electrospinning. This indicated a formation of a less-ordered amorphous 
structure because of the acidic gelatin solution (Mindru et al., 2007; Elliot 
et al., 2009; Siimon et al., 2014; Etxabide et al., 2015). The presence of an 
ordered helical structure was also hindered in the G20 fibers. That has 
been reported to be caused by elevated temperatures and by using solvent 
mixtures containing acetic acid and dimethylformamide (DMF) (Kozlov and 
Burdygina, 1983). The spectral analysis did not reveal any additional changes 
to the secondary structure of gelatin after thermal crosslinking. 
The glycation process is known to be promoted by high temperature and 
the increased amount of the crosslinking agent (Siimon et al., 2014, 2015; 
Etxabide et al., 2015). Permanent changes to the fibrous structure of gelatin 
substrates were detected by the changes to the CO vibrations at 1029 and 
1080 cm-1 (Figure 8B). These changes were attributed to the non-enzymatic 
Maillard reaction between the carbonyl group of glucose and amino group of 
gelatin (Siimon et al., 2014, 2015; Etxabide et al., 2015). 
Figure  8. A: Conventional DSC thermograms of untreated gelatin (---), 
noncrosslinked (nonCL) (···) and crosslinked (CL) (─) G25 and G20 gelatin 
substrates. B: Pretreated ATR-FTIR spectra of nonCL (···) and CL (─) G25 
gelatin substrates in the spectral range from 900 to 1750 cm-1.
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5.1.4. Ink-substrate interactions in printed dosage forms (I, IV) 
The wettability and absorption properties of the substrates allow 
estimating the drug-loading capacity and the drying conditions for obtaining 
solid dosage forms by printing. The drying process of the printed dosage 
forms has similarities with the production of solvent-cast films (Boateng et 
al., 2009). In the optimization of the drying process, it is crucial to avoid the 
sedimentation of the solid particles and the solidification of the film surface 
to ensure the physical stability of the solvent-cast films (Siemann, 2005). 
Hence, the dried equilibrium state of the printed dosage forms is dependent 
on the drying environment and the properties of the substrate and ink 
components, such as the absorption capacity, the droplet volume and the 
solvent evaporation rate (Sandler et al., 2011; Genina et al., 2013; Wickström 
et al., 2015). Due to the porous structure of copy paper, printing up to 9 layers 
of water-based inks was shown to be feasible without any intermediate 
drying steps, whereas the ink solidification on the substrates with lower 
absorbability required a drying time of 1  h at ambient conditions (Genina 
et al., 2013). However, for the removal of residual organic solvents drying at 
elevated temperature with or without a vacuum oven should be considered 
(Wickström et al., 2015). 
In the first study (I), the physical interactions between the ink solutions 
and the different substrates were investigated by contact angle measurements 
during the liquid absorption process. The extensive spreading of the CAF ink 
on the carriers was prevented by the higher surface tension of the solution 
compared to the LOP ink (Figure 9). The formation of cavities was visually 
observed on the thin (0.10  ±  0.01  mm, n  =  10) HPC films leading to the 
interaction with the impermeable sub-liner for both ink solutions. The 
decreased size of the ink droplets on the PET and HPC films was mainly 
attributed to the solvent evaporation. On the icing sheet, the ink absorption 
was noticeably faster without any evident cavities due to the higher thickness 
(0.45 ± 0.06 mm, n = 10) of the substrate compared to the HPC film.
The physical stability of electrospun fibrous substrates was evaluated 
at high humidity (RH of 70%) conditions (IV). The moisture uptake was 
shown to be affected by the diameter and the packing density of the fibers, 
giving noticeable differences between nano-fibrous G25 and micro-fibrous 
G20 substrates (Figure 10). The moisture uptake analysis allowed predicting 
their behavior during storage and printing. At high humidity, the nonCL 
fiber substrates turned into unfavorably hard and brittle film-like structures. 
However, the CL fiber mats maintained their initial appearance with a slight 
contraction of the edges of the micro-fibrous G20 scaffolds. 
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Figure 9. Wettability of caffeine (CAF) (A) and loperamide hydrochloride (LOP) 
(B) inks on polyethylene terephthalate (PET) film, hydroxypropyl cellulose 
(HPC) film and icing sheet with values for contact angle (°) as mean ± standard 
deviation, n = 3.
Figure  10. Moisture uptake (%) of non-crosslinked (nonCL) and crosslinked 
(CL) G25 and G20 gelatin substrates after 2 or 25 days presented as 
mean with standard deviation bars, n = 3.
5.2. Preparation and characterization of printed dosage forms 
The printed dosage forms were prepared according to process scheme 
presented in Table 7. In the inkjet-printed systems, the fixed spatial resolution 
defined the deposition of the picoliter-size droplets. The printed area on the 
substrates was visible with clear borders on all substrates except for the icing 
sheet, where a single layer of a colorless ink solution could not be detected 
due to the extensive absorption of the ink into the substrate. 
In the flexographically printed formulations, the nanosuspension inks 
were deposited in 10 consecutive layers on the substrates. The printed 
formulations were obtained with distinct micro-scale pattern from the 
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anilox roll structure. In addition, the manual adjustment of the printing rolls 
during the process caused the occurrence of smeared edges from the slight 
displacement of the printed layers. 
 Table 7. Experimental setup and design of the printed drug formulations. 
5.2.1. Morphology of printed dosage forms (I, III, IV)
The surface of the printed formulations with CAF and LOP was visualized 
by SEM (Figure 11) (I). The CAF ink crystallized on all the substrates with a 
dose-dependent amount and size of the needle-shaped crystals. The uniform 
distribution of the crystalline CAF was seen in low-dose formulations on 
PET film, whereas in the high-dose formulations inhomogeneous coverage 
was caused by the merging of the ink droplets prior to crystallization. 
On the surface of the HPC film, the crystallization of the CAF ink was less 
pronounced due to the partial penetration of the ink into the substrate. The 
amount of the crystallized CAF on the surface of the icing sheet was lower 
compared to PET and HPC substrates. Overall, the results correlated with the 
contact angle measurements indicating that the ink behavior on the surface 
was dependent on the absorptivity of the substrates. 
The LOP ink solidified on the impermeable PET film in single (at low 
resolution) or merged (at high resolution) droplets. On the smooth HPC 
film, the water-based LOP ink merged into the substrate with small visible 
droplets on the surface of the high-dose formulations. The LOP ink was 
not detectable on the icing sheet, because of the extensive absorption of the 
ink into the substrate matrix. Nevertheless, the SEM-EDX could detect the 
chloride element of LOP salt at low levels on the surface of the icing sheet in 
the high-dose formulations. 
The ITR and IND nanosuspensions were distributed uniformly on the 
substrates by flexographic printing without any evident agglomeration 
(Figure 12) (III). However, the close contact between the patterned printing 
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rolls and the substrates attributed to the uneven topography of the printed 
formulations. The partial penetration of the ink into the matrix of the rice 
sheet was contributed to the higher porosity of the edible substrate.
Figure  11. SEM images of inkjet-printed caffeine (CAF) and loperamide 
hydrochloride (LOP) on polyethylene terephthalate (PET) film, hydroxypropyl 
cellulose (HPC) film and icing sheet at drop spacing of 10 μm; 30× (scale bar of 
200 μm) and 2500× (scale bar of 2 μm) magnifications.
46
Results and discussion
Figure  12. SEM images of flexographically printed itraconazole (ITR) and 
indomethacin (IND) on transparency film (TF), rice paper and rice sheet; 30× 
(scale bar of 200 μm) and 5000× (scale bar of 1 μm) magnifications. 
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The electrospun gelatin substrates consisted of individually detectable 
fibers even after crosslinking (Figure  13A) (IV). The surface of the printed 
dosage forms was smoother compared to the unprinted substrates due to 
the swelling and adhesion of the gelatin fibers (Figure  13B). Furthermore, 
the mechanical testing indicated that the deposition of the ink solution 
had no significant effect on the puncture strength of the dosage forms with 
LH printed on CL gelatin substrates compared to unprinted fiber mats. The 
elasticity (expressed as the elongation at break) of the final preparations was 
enhanced by approximately 2-fold. Recently, Preis et al. (2014) studied the 
mechanical strength of several orodispersible and buccal film formulations 
that are commercially available. The mechanical properties of the printed 
dosage forms on the CL fiber matrices in the current study (IV) were 
comparable with the marketed film products analyzed by Preis et al. (2014), 
indicating that these printed dosage forms could be suitable for oromucosal 
drug delivery. 
Figure  13. SEM images of the crosslinked (CL) G25 gelatin substrate (A) and 
lidocaine hydrochloride printed on CL G25 substrate (B); 10000× (scale bar of 
2 μm) magnification. 
5.2.2. Solid state characterization of printed pharmaceuticals 
5.2.2.1. Caffeine (I, II) 
The raw material used for the ink preparation was confirmed as CAF 
anhydrous form II based on the comparison with the previously reported 
data (Jørgensen et al., 2002; Wyttenbach et al., 2007). At least a partial 
crystallization of CAF into its stable anhydrous form II was detected in the 
printed formulations by XRD with a characteristic 2θ angle at approximately 
12° (Figure 14A). 
The thermal analysis of the raw material and the CAF that was detached 
from the PET film demonstrated a polymorphic transformation of an 
anhydrous form II into form I at 142  °C (onset) with a melting endotherm 
48
Results and discussion
at 236 °C (Figure 14B). In addition, a low intensity endotherm at 30–140 °C 
suggested the moisture elimination from the crystalline material or a 
dehydration process of a non-stoichiometric CAF hydrate (Wyttenbach et al., 
2007). CAF was not detectable on edible substrates by DSC. 
CAF anhydrous form II exhibits several characteristic absorbance bands 
in the “fingerprint” region of the IR spectra from 400 to 1700 cm-1 (Kesimli 
et al., 2003; Nolasco et al., 2006; Srivastava and Singh, 2013). The spectral 
characteristics of CAF anhydrous form II were detected on the ATR-FTIR 
spectra of the printed formulations. The absorbance bands at 444, 481, 610, 
1025, 1358 and 1403  cm-1 showed high specificity towards the quantitative 
content of crystalline CAF without any overlapping from the residual PG and 
the PET film. 
Figure  14. A: X-ray diffractograms of caffeine (CAF) anhydrous form II 
(a), printed CAF detached from polyethylene terephthalate (PET) film (b), 
hydroxypropyl cellulose (HPC) film (c), CAF printed on HPC film (d), icing 
sheet (e) and CAF printed on icing sheet (f). Diffractograms are offset in 
intensity for clarity. B: DSC thermograms of CAF anhydrous form II (a), printed 
CAF detached from PET film (b), CAF printed on HPC film (c) and CAF 
printed on icing sheet (d). Thermograms are offset in y-axis for clarity. The CAF 
formulations were printed at a drop spacing of 10 μm. 
5.2.2.2. Loperamide hydrochloride (I, II) 
The data from the XRD and DSC analysis of LOP was compared to the 
previously reported solid state forms of LOP (Van Rompay and Carter, 1990). 
The results showed that LOP anhydrous form I was used for the preparation 
of the printed dosage forms (Figure 15A).
The X-ray diffractograms of the printed dosage forms reflected mainly 
the crystalline components of the substrate materials without any observed 
crystalline reflections for the printed LOP on all three substrates. The 
printed LOP that was detached from the PET film exhibited a low degree 
of crystallinity without any evident proof about its polymorphic form 
(Figure 15A). 
The thermal analysis of the LOP that was removed from the PET film 
exhibited an exothermal event at 106 °C (onset) with a subsequent melting of 
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an anhydrous form II at 218  °C (Figure  15B). The low drug amount in the 
intact printed formulations hindered the thermal analysis of the printed LOP 
on edible substrates. 
In addition, the IR spectra of the printed LOP formulations was matched 
with the previously reported data on the solid state forms of LOP (Weuts et 
al., 2004; Bagmar Ujwala et al., 2013; Bruni et al., 2013). The printed drug 
showed some characteristic features for LOP anhydrous form I on the ATR-
FTIR spectra in the spectral range from 500 to 1650  cm-1. The absorbance 
bands at 541, 641, 1385, 1449 and 1625 cm-1 were characteristic for crystalline 
LOP. However, the presence of an amorphous LOP was suggested by the small 
changes in the intensity and shape of the absorbance bands. The absorbance 
bands for –OH vibrations of LOP at 3560 and 3390 cm-1 have been reported 
to be absent in the IR spectrum of LOP in an amorphous state (Weuts et 
al., 2004). The presence of an amorphous LOP could not be verified by the 
spectral analysis of the printed formulations due to a clear overlapping with 
the PG spectrum in the spectral range from 2800 to 3500 cm-1. 
The results from the solid state analysis indicated that the solidified LOP 
in the printed formulations was in a molecularly dispersed or amorphous 
state. This was obviously due to the high content of the non-volatile PG in 
the printed formulations that is known to hinder the crystallization of active 
compounds (Cilurzo et al., 2005).
Figure  15. A: X-ray diffractograms of loperamide hydrochloride (LOP) 
anhydrous form I (a), printed LOP detached from polyethylene terephthalate 
(PET) film (b), hydroxypropyl cellulose (HPC) film (c), LOP printed on HPC 
film (d), icing sheet (e) and LOP printed on icing sheet (f). Diffractograms are 
offset in intensity for clarity. B: DSC thermograms of LOP anhydrous form I (a), 
printed LOP detached from PET film (b), LOP printed on HPC film (c) and LOP 
printed on icing sheet (d). Thermograms are offset in y-axis for clarity. The LOP 
formulations were printed at a drop spacing of 10 μm. 
5.2.2.3. Itraconazole (III) 
The solid state analysis of the nanosuspensions is crucial, since active 
compounds in an amorphous state could also be obtained by milling due to 
the mechanical disruption of the crystalline structure and/or by the strong 
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interactions between the drug and the stabilizing agents (Müller and Peters, 
2001; Kayaert and Van den Mooter, 2012). 
Due to the low weight fraction of the active compound in the final 
formulations and the nano-size range of the printed particles, the solid state 
analysis of the printed formulations was limited (Phadnis et al., 1997; Jenkins 
and Snyder, 1996). Nevertheless, the printed ITR on the surface of the TF film 
was detectable by XRD at low levels of intensity (Figure 16A). The obtained 
X-ray diffractograms were compared with the ITR-specific X-ray reflections 
reported earlier by Van Eerdenbrugh et al. (2008b). On the diffractograms, 
the reflections at 14.5°, 17.6° and 20.4°  2θ angles indicated the presence of 
ITR in a stable crystalline form (Figure 16A). The results were in compliance 
with a previous study by Liu et al. (2011), where it was presented that the 
crystalline state of the API in aqueous nanosuspensions was not altered by the 
milling process and the subsequent solidification by freeze-drying. 
5.2.2.4. Indomethacin (III) 
The results from the XRD analysis of the printed formulations indicated 
that IND was at least partially present in a crystalline state on the TF film. 
Similarly to the ITR formulations, the reflections from the substrate 
material contributed most to the X-ray diffractograms (Figure  16B). The 
polymorphic α, β and γ forms have been previously differentiated by XRD 
with some possible overlapping of the diffraction peaks in polymorphic 
mixtures (Kaneniwa et al., 1985). A single reflection at 11.7° was attributed 
to the stable γ form of IND in the printed formulations. The presence of IND 
in an amorphous state was unlikely due to the production of an aqueous 
nanosuspension (Ali et al., 2011; Liu et al., 2011).
 
Figure  16. X-ray diffractograms of itraconazole (ITR) (A) and indomethacin 
(IND) (B) printed on the transparency film (TF). Diffractograms are offset in 
intensity for clarity.
5.2.2.5. Lidocaine hydrochloride (IV) 
The LH monohydrate was used as the raw material in the ink formulations. 
The LH monohydrate exhibited a melting endotherm at 79  °C (data not 
shown). On the DSC thermograms of the printed dosage forms, the 
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characteristic endotherm of LH monohydrate was superposed by the 
thermal events of water evaporation and the denaturation of gelatin fibers. 
LH anhydrous form has a melting point at approximately 130  °C (Koehler 
and Hefferren, 1964). This was not observed on any of the obtained DSC 
thermograms. However, further MT-DSC analysis allowed detecting the 
increase of heat capacity (Cp) in the printed dosage forms with LH compared 
to the unprinted substrates (Figure  17A). No crystallinity of the drug was 
detected in the dosage forms by XRD (Figure 17B).  
Figure  17. A: Modulated DSC (MT-DSC) thermograms (reversing heat flow 
signal) of crosslinked (CL) G25 gelatin substrate (─) and lidocaine hydrochloride 
(LH) printed on CL G25 substrate (–·–). B: X-ray diffractograms of LH 
monohydrate (a), physical mixture corresponding to the dosage form with LH 
printed on CL G25 substrate (b), CL G25 substrate (c) and LH printed on CL 
G25 substrate (d). Diffractograms are offset in intensity for clarity. 
The ATR-FTIR spectral analysis indicated the formation of a solidified 
ink layer on the electrospun substrates. Small spectral changes (e.g., peak 
broadening, shifting, merging and/or change of intensity) to the absorbance 
bands of LH monohydrate at 1477, 984, 952, 773, 716 and 691  cm-1 were 
detected in the printed dosage forms. In addition, LH monohydrate exhibits 
characteristic NH stretching vibrations at 2200–3000  cm-1 (Neville and 
Regnier, 1969). However, these absorbance bands were not detectable on the 
spectra of the printed dosage forms, suggesting that LH monohydrate was not 
crystallized after printing. 
Thus, based on the solid state analysis, LH was present most likely in a 
molecularly dispersed state after inkjet printing. The non-crystalline state 
of the drug was stabilized by the homogeneous distribution of the printing. 
Furthermore, the solubilizing effect of PG contributed to the inhibition of the 
crystallization of the printed API (Cilurzo et al., 2005).
5.3. Dosing accuracy and flexibility of printing 
5.3.1. Content analysis of printed dosage forms 
The theoretical dose of LOP (ink concentration of 50  mg/ml) in the 
printed dosage forms ranged from 0.08 to 2.0 mg (I, II). The obtained drug 
52
Results and discussion
content was therapeutically relevant for pediatric administration with the 
single dose of 0.1  mg/kg and for adults with a single dose of 2–4  mg.  The 
CAF (ink concentration of 20 mg/ml) was printed in the range from 0.03 to 
0.8 mg (I, II). The content analysis of the printed formulations revealed that 
the actual amount of the deposited drugs was slightly higher compared to 
the theoretical dose. Dong et al. (2006) reported that the droplet size of the 
inks was increased due to the differences in the physicochemical properties 
of the inks. Thus, the droplet size and dose validation is needed for each ink 
formulation separately. 
The drug content in the dosage forms with LH printed on an area of 
2 cm2 was obtained in a low therapeutically relevant dose (IV). The measured 
content (2.85  ±  0.06  mg, n  =  6) showed no significant deviation from the 
theoretically expected amount (2.84  mg). However, degradation up to 18% 
from the initial content of LH derived from the hydrolysis of the amide 
group was observed over a short-time storage period of 8 months at room 
temperature. 
The drug content of ITR and IND in the flexographically printed 
formulations with 10 layers of ink on 0.5  cm2 was well below therapeutic 
levels ranging from 40 to 380 µg and from 110 to 270 µg, respectively (III). 
The results indicated that the printing process was not optimal for the precise 
dosing of the nanosuspension inks. Furthermore, an insufficient homogeneity 
of the nanosuspensions and possible sedimentation of the particles could 
explain the fluctuation in the deposited drug amount. 
The dosing accuracy of the inkjet printing was significantly superior 
to the flexographic printing. The relative standard deviation (RSD) values 
below 4% were obtained for all inkjet-printed formulations, whereas in the 
flexographically printed formulations the RSD values for drug content varied 
from 8 to 39%. 
5.3.2. Dosing flexibility of inkjet-printed dosage forms (I) 
The drug content in the printed formulations can be adjusted by various 
methods, such as changing the size of the printed area, the number of printed 
layers and/or optimizing the concentration of the inks (Buanz et al., 2011; 
Janßen et al., 2013; Raijada et al., 2013; Wickström et al., 2015). On the other 
hand, the porosity, absorbability and thickness of the substrates also affect the 
loading capacity of the printed formulations (Sandler et al., 2011). 
The drug content in the inkjet-printed dosage forms was adjusted by 
varying the printing resolution or the size of the printed area. Expectedly, 
adjusting the size of the dosage forms correlated linearly with the printed 
drug amount (Figure 18A–B). Whereas the drug content in the dosage forms 
printed on 4 cm2 increased with the increasing resolution as a power function 
(Figure  18C–D). The behavior of the printed inks on the PET substrate 
correlated with the obtained drug content. The size of the solidified droplets 
in the LOP formulations as well as the crystallization of CAF was noticeably 
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increased above the resolution of 846  dpi (DS of 30  µm) as the distance 
between the jetted droplets decreased. 
Figure  18. Left: Dosing flexibility of caffeine (CAF) (A) and loperamide 
hydrochloride (LOP) (B) by varying the size of the printed patterns, while the 
resolution remained constant (drop spacing of 10 µm). Right: Dosing flexibility 
of CAF (C) and LOP (D) by varying the resolution of the printed patterns, while 
the size of the dosage form remained constant (4 cm2). Drug content is presented 
in theoretical (♦) and measured content (○) as mean with standard deviation 
bars, n = 3. R2 – correlation coefficient. 
5.4. Spectral quantification of printed dosage forms (II) 
A quantitative analysis was conducted on the ATR-FTIR spectra of the 
formulations with printed CAF and LOP on impermeable PET substrate. 
The use of an ATR setup allowed obtaining API-specific spectral information 
directly from the surface of the planar printed formulations (Fahrenfort, 1961; 
Offermann et al., 1995). The collected spectra of the CAF and LOP printed 
formulations were subject to univariate and multivariate data analysis. 
5.4.1. Univariate data analysis of infrared spectra 
In the univariate data analysis, the peak area and height of qualitatively 
relevant absorbance bands were correlated with the printing resolution that 
was expressed as DS values and the drug content (Figure 19). 
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Figure  19. Pretreated ATR-FTIR spectra of caffeine (CAF) anhydrous form II 
(A), loperamide hydrochloride (LOP) anhydrous form I (B) and the printed 
formulations of both drugs with the increasing resolution – drop spacing (DS) 
from 50 µm (DS50) to 10 µm (DS10). Spectra are offset in absorbance for clarity. 
In drug formulations with printed CAF or LOP, the height and/or area 
of the selected individual absorbance bands was found to have a linear 
relationship with the DS and a logarithmic correlation with the actual drug 
amount. Specific examples with the highest correlation coefficients are 
shown in Figure  20. It was noted, that the formulations with CAF allowed 
obtaining a better quantitative relationship due to a uniform distribution 
of the crystalline drug on the printed surface compared to the unevenly 
spread LOP ink. The analysis of the printed LOP was dependent on the 
size of the solidified droplets that increased with the resolution (decreased 
DS). The interference from the underlying PET substrate decreased due 
to the coalescence of the droplets and provided a more uniform coverage 
of the analysis area of the ATR FTIR spectroscope. The effect of the ink 
distribution on the drug quantification can be clearly detected between the 
LOP formulations printed with DS of 25 or 30 µm (Figure 20). The narrower 
selection of the analyzed samples improved the correlation coefficient (R2) 
between the peak height and the drug content or DS, but not the predictive 
properties of the correlation models (Figure 20).
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Figure  20. Left: Drop spacing (A) and caffeine (CAF) measured content (B) 
correlation plots with peak area at 610 cm-1 in the calibration (○) and test (▲) 
sets. Right: Drop spacing (C) and loperamide hydrochloride (LOP) measured 
content (D) correlation plots with peak height at 1385 cm-1 in the calibration 
(○) and test (▲) sets. R2 – correlation coefficient; RMSEP – Root Mean Square 
Error of Prediction. 
5.4.2. Multivariate data analysis of infrared spectra 
In-line and on-line methods, such as Raman and NIR spectroscopy, are 
applicable for monitoring the qualitative and quantitative properties of drug 
preparations during the manufacturing process (Auer et al., 2003; Helmy 
et al., 2003; Rajalahti and Kvalheim, 2011; Mazurek and Szostak, 2012). 
Besides that, IR-based analysis tools coupled with chemometrics provide a 
fast and non-destructive alternative for at-line quality control compared to 
conventional and time-consuming off-line quantification methods (Pöllänen 
et al., 2005; Boyer et al., 2006). 
The correlation models between the spectral data and the DS of printing 
could predict and verify the printing parameter value for the CAF and LOP 
formulations. More interestingly, the correlations between the spectral data 
and the printed drug content were evaluated for the quantitative quality 
control of the printed formulations. Based on the observations from the 
univariate analysis, the drug content was used in logarithmic values to 
establish linear models in the PLS regression analysis. The evaluation of the 
statistical parameters showed that by adjusting the model attributes, such as 
specifying the spectral range and applying different scaling algorithms and/
or pre-processing filters, the performance of the PLS regression models 
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increased. 
The significant changes in the spectral data (independent X-variables) 
for the prediction of drug content (dependent Y-variables) are demonstrated 
in the PLS weights plots (Figure  21). In the PLS regression model for CAF 
quantification, the first latent variable (LV) explained over 70% of the data 
by differentiating between the CAF and PG content. The relevant absorbance 
bands from the univariate analysis contributed also to the PLS regression 
models without any significant disturbance from the PET substrate. However, 
the first LV in the PLS regression model for LOP quantification explained 
approximately 86% of the spectral variation derived from the differences 
between the deposited ink components and the PET substrate. As expected 
from the univariate analysis, the division of the data into two clusters was 
also observed in the PLS regression analysis. The LOP and PG content within 
the sub-clusters of the data was in correlation with the second LV. Smaller 
spectral changes that were not apparent from the univariate analysis were 
incorporated into the PLS regression models by the additional LVs. 
Interestingly, the multivariate data analysis could obtain good quantitative 
correlations between the LOP formulations with inhomogeneous drug 
distribution. The obtained PLS regression models showed good predictability 
and high correlations between the measured and predicted drug content 
(Figure 22). The quantitative analysis of the printed formulations was shown 
to be influenced by the performance range of the analysis method and the 
printing quality.
Figure 21. Weights of partial least squares (PLS) latent variables (LVs) for the 
quantification of caffeine (CAF) (A) and loperamide hydrochloride (LOP) (B) 
in the printed formulations. Model parameters: spectral range of 400–1750 cm-1, 
Standard Normal Variate (SNV) pre-processing, mean centering (Ctr). The main 
absorbance bands for the corresponding drug (*), PET substrate (♦) and PG (○) 
that contributed to the first LV are marked. Weights are offset for clarity.
Results and discussion
57
Figure  22. Prediction of caffeine (CAF) (A) and loperamide hydrochloride 
(LOP) (B) content in the printed formulations. Model parameters: spectral 
range of 400–1750 cm-1, Standard Normal Variate (SNV) pre-processing, mean 
centering (Ctr). R2 – correlation coefficient; RMSEP – Root Mean Square Error 
of Prediction. 
5.4.3. Evaluation of spectral quantification for quality control of 
printed dosage forms
The ATR-FTIR spectroscopy together with the multivariate data analysis 
could be applied to distinguish between the different components in complex 
formulations (e.g., printed dosage forms) and to provide a feasible non-
destructive quantification method for the quality control of printed dosage 
forms. 
The univariate data analysis determined the relationship between the 
spectra and the drug content in the printed formulations. Unlike PLS 
regression, where linear correlation between the variables is expected, the 
univariate method allowed applying various types of correlation models. 
Furthermore, some quantitative correlations were obtained with separated 
and high intensity absorbance bands.
The uniform distribution of the drug in the formulations has shown to be 
crucial in obtaining reliable spectroscopic quantification models (Mazurek 
and Szostak, 2011, 2012). The variations caused by the uneven coverage of 
the substrate were seen in the univariate spectral analysis of the printed LOP 
formulations. These differences were not apparent in the multivariate analysis 
that enabled the quantification of the printed pharmaceuticals in the systems 
with heterogeneous distribution of ingredients and/or spectral overlapping. 
5.5. In vitro drug release from solid nanoparticulate systems 
prepared by flexographic printing (III) 
The dissolution rate of an active compound is directly affected by the 
available surface area of particles that is increased non-linearly with the 
reduction of particle size (Noyes and Whitney, 1897; Merisko-Liversidge and 
Liversidge, 2008). The Noyes-Whitney equation (Equation  2) determines 
that the dissolution rate (dC/dt) of the solute is proportional to the available 
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surface area of the solute particle (A), diffusion coefficient (D), concentration 
difference between the saturation solubility (Cs) in the diffusion layer and the 
solute concentration (C) in the bulk solution, and inversely proportional to 
the thickness of the diffusion layer (h). 
The preparation of nanosuspensions increases the effective surface area 
of the particles. Thus, this could subsequently improve the dissolution rate 
of drug substances. In addition, the increased dissolution rate is presumed to 
promote bioavailability of solubility-limited APIs (Müller and Peters, 1998). 
The dissolution profiles of the nanoparticulate formulations were obtained 
with high deviations from the estimated drug content and notable intersample 
variations (Figure  23). The in vitro drug release from the impermeable 
TF substrate was comparable to the enhanced performance of the plain 
nanosuspensions. This was explained primarily by the even ink distribution 
that hinder the agglomeration of the particles upon solidification. The release 
of ITR and IND from the solid dosage forms printed on edible substrates 
was prolonged due to the incorporation of the drug particles into the porous 
substrate. However, these apparent advantages might not be expressed in 
the physiological conditions for nanocrystalline DDS containing APIs with 
pH-dependent solubility (Sarnes et al., 2014). 
Figure  23. Dissolution profiles of itraconazole (ITR) (A) and indomethacin 
(IND) (B) powder (×), suspension (■) and printed samples on transparency film 
(TF) (▲), rice sheet (●) and rice paper (♦). Drug release is presented as mean 
with standard deviation bars, n = 3. 
5.6. Combination drug delivery system with two active 
compounds (IV) 
5.6.1. Preparation of combination drug delivery system 
A combination DDS was prepared by combining electrospinning and 
inkjet printing technologies (Figure  24). This proof-of-concept formulation 
contained LH that was deposited on the PRX-loaded electrospun 
(Equation 2)
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substrates (G20-PRX) by inkjet printing. It was suggested that similar drug 
combinations with anti-inflammatory and anesthetic APIs could complement 
the prevention and treatment of oromucosal infections.
 
Figure  21. Experimental design and setup of the printed combination drug 
delivery system.
5.6.2. Characterization of drug-loaded electrospun substrates
The drug-loaded G20-PRX fibrous substrates were prepared with a 
thickness of 0.06 ± 0.02 mm (n = 3). The electrospun G20-PRX microfibers 
showed a 13.3% increase in the diameter of the fibers compared to the 
unloaded G20 fibers (Table  8). The evaporation of the residual solvents 
during thermal crosslinking affected the size of the drug-loaded G20-PRX 
fibers showing a significant decrease (by 12.7%) in the average diameter of the 
fibers. The crosslinking improved the strength and elasticity of the G20-PRX 
fibers (Table  8). It was noted that the physical properties of the substrates 
were slightly affected by the incorporation of PRX into to the fibers; however, 
the effect was less pronounced after crosslinking. 
Table  8. Average fiber diameter and physical properties of non-crosslinked 
(nonCL) and crosslinked (CL) piroxicam-loaded gelatin substrates (G20-PRX). 
Fiber 
diametera 
(nm)
Puncture testb Tensile testb
Burst 
strength 
(mN/mm2)
Elongation 
at break (%)
Tensile 
strength 
(N/mm2)
Elongation 
at break (%)
Elastic 
modulus 
(kPa)
nonCL G20-PRX 1477.6 ± 217.5 37.8 ± 8.8 0.6 ± 0.1 1.6 ± 0.4 1.3 ± 0.2 16.2 ± 1.4
CL G20-PRX 1301.1 ± 216.9 71.7 ± 12.9 1.7 ± 0.1 2.5 ± 0.03 2.1 ± 0.4 9.0 ± 2.9
amean ± standard deviation, n = 100. bmean ± standard deviation, n = 3-5.
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The amorphous structure of gelatin was confirmed by XRD and ATR-FTIR 
spectroscopy also within the drug-loaded G20-PRX fibers (data not shown). 
The PRX-loaded fibrous scaffolds were stabilized by the Maillard reaction 
shown by the characteristic features on the DSC thermograms and the ATR-
FTIR spectra similar to the unloaded G20 fibers. However, the MT-DSC 
thermal analysis showed that the thermal stability of the fibers was influenced 
by the addition of PRX, showing an approximately 20  °C decrease in the 
helix-coil transition temperature of gelatin. 
The APIs in an amorphous state can be stabilized by the incorporation of 
the drug molecules into the electrospun polymer fibers (Vrbata et al., 2013; 
Paaver et al., 2014, 2015; Farooq et al., 2015). Therefore, thermal, X-ray 
diffraction and spectroscopic analyses were conducted to determine the solid 
state of PRX in the electrospun fibers. The characteristic thermal events for 
PRX were not detectable in the nonCL fibers due to the inclusion of PRX 
within the gelatin fibers and the overlapping with the melting endotherm 
of glucose at 149.5  °C (onset at 125.8  °C) (Figure  25A). The absence of a 
melting endotherm indicated that that PRX was incorporated into the fibers 
in an amorphous state. However, in the CL G20-PRX fibers an endotherm at 
173.1 °C (onset at 150.2 °C) was detected (Figure 25A). It was suggested that 
in the thermally treated fibers the amorphous PRX crystallized into its least 
stable anhydrous form III with subsequent melting as shown previously for 
amorphous PRX and/or its solid dispersions (Vrečer, et al., 2003; Kogermann 
et al., 2011). 
The absorbance bands at 1436, 875 and 773 cm-1 on the ATR-FTIR spectra 
were attributed to PRX in the nonCL and CL drug-loaded fibers. However, 
several characteristic absorbance bands for specific crystalline forms of 
PRX (anhydrous forms I, II, III and monohydrate) assigned by Vrečer, et al. 
(2003) and Taddei et al. (2001) were not present in the measured spectra. 
Furthermore, the changes in the spectral range from 3300 to 3400  cm-1 
indicated the stabilization of the amorphous PRX through intermolecular 
interactions with gelatin. The detected disappearance of the N–H stretching 
vibrational mode of PRX at 3337 cm-1 has been assigned to hydrogen-bonding 
between NH group of PRX and >N– and C=O functional groups of polymers 
(Tantishaiyakul et al., 1999; Lust et al., 2015). The PRX in an amorphous state 
within the electrospun G20-PRX fibers before and after crosslinking was 
confirmed by the XRD analysis (Figure 25B). 
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Figure 25. A: Modulated DSC (MT-DSC) (total heat flow signal) thermograms 
of non-crosslinked (nonCL) and crosslinked (CL) piroxicam-loaded gelatin 
substrates (G20-PRX). Thermograms are offset in y-axis for clarity. B: X-ray 
diffractograms of PRX anhydrous form II (c), physical mixture corresponding 
to the formulation of G20-PRX substrate (d), nonCL G20 (e) and G20-PRX (f) 
substrates and CL G20 (g) and G20-PRX (h) gelatin substrates. Diffractograms 
are offset in intensity for clarity. 
5.6.3. Characterization of combination drug delivery system 
The drug loading of the CL G20-PRX substrate corresponded well with the 
theoretical content, containing 6.2 ± 0.2% (n = 3) of PRX in the fibers. The 
chemical stability of the API showed a non-significant loss (<  5%) after the 
thermal treatment at 130 °C. The PRX content of 0.35 ± 0.01 mg per a printed 
area of 2 cm2 remained constant over a short-term stability study of 4 months. 
The printed DDS contained 2.18  mg of LH per a printed area of 2  cm2 
(initial theoretical dose). Drug degradation of approximately 30% was 
detected during a short-term stability study of 4 months. The hydrolysis of LH 
was more distinct in the dual DDS compared to the single drug system with 
LH printed on unloaded G25 gelatin substrates. In the latter formulation, an 
approximately 8% loss of LH content was detected after 4 months. 
The solid state analysis of the combination DDS showed that the printing 
did not affect the amorphous state of PRX. A characteristic endotherm at 
175.7  °C for PRX in the drug-loaded gelatin fibers was identified also on 
the DSC thermograms of the printed DDS. The XRD analysis showed no 
crystallization of PRX or LH in the dual DDS. It was proposed that the small 
volume of the ink droplets and the fast evaporation rate of the solvents could 
not promote the crystallization of PRX. In addition, the printing provided 
a stabilizing barrier through the uniform deposition of the molecularly 
dispersed LH on the surface of the fibrous substrates. 
5.6.4. In vitro drug release from combination drug delivery system
The results showed that the release kinetics of PRX and LH from the 
dual DDS were comparable to the single drug formulations (Figure  26). 
This suggested that a combination method for preparing complex DDS with 
multiple APIs could provide possibilities for controlling the single drug 
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performance in the dosage forms separately. 
The electrospun G20-PRX substrate showed an immediate drug release 
profile with a high initial burst release that was decreased approximately 
2-fold after crosslinking (Figure  26A). The drug release from the surface 
of the electrospun fibers has been reported to be the main cause for the 
burst effect (Agarwal et al., 2008; Hu et al., 2014; Nguyen et al., 2012). PRX 
monohydrate has a lower aqueous solubility compared to its crystalline 
counterparts (Jinno et al., 2000; Paaver et al., 2012). Thus, in the nonCL fibers, 
the formation of a monohydrate form was presumed due to the decreased 
amount of dissolved PRX after few minutes. The addition of LH by printing 
did not have any noticeable effect on the PRX release profile from the 
combination DDS compared to the CL G20-PRX substrate. 
The drug release of LH was not dependent on the printing substrate, 
showing immediate release from the dosage forms printed on unloaded G25 
and drug-loaded G20-PRX gelatin substrates (Figure  26B). The addition 
of a backing layer to such printed dosage forms could further improve the 
performance of oromucosal dosage forms by controlling the direction of the 
drug release (Preis et al., 2014, 2015).
Figure  26. A. Drug release (%) of piroxicam (PRX) from non-crosslinked 
(nonCL) (♦) and crosslinked (CL) (♦) drug-loaded gelatin substrates (G20-PRX), 
and from the combination drug delivery system with lidocaine hydrochloride 
(LH) printed on CL G20-PRX substrate (■). B. Drug release (%) of LH from 
the printed dosage forms on CL G25 (▲) and G20-PRX (▲) substrates. Drug 
release is presented as mean with standard deviation bars, n = 2.
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6. Conclusions and outlook 
The focus of this thesis was to gain in depth knowledge about the 
development of drug delivery systems (DDS) by two-dimensional (2D) 
printing technology. 
The drug-containing solutions or nanosuspensions were prepared as 
pharmaceutical inks for the inkjet or flexographic printing, respectively. 
The printability of the ink solutions was successfully estimated based on the 
analysis of the viscosity and the surface tension of the inks. Furthermore, the 
gelatin-based electrospun fibrous matrices were successfully utilized as carrier 
substrates in the inkjet-printed dosage forms after improving their mechanical 
strength by thermal crosslinking. 
Solid dosage forms were obtained after the deposition of the 
pharmaceutical inks on biodegradable carrier matrices by means of inkjet 
or flexographic printing. The solid state of the printed pharmaceuticals was 
shown to be affected by the physicochemical properties of the drug, the ink 
formulation and the absorbability of the substrate. On the edible substrates, 
the printed pharmaceuticals penetrated at least partially into the carrier 
matrices. The active compounds were detected in crystalline or molecularly 
dispersed state in the inkjet-printed dosage forms. Whereas the solid 
nanoparticulate systems obtained by flexographic printing of crystalline 
nanosuspensions exhibited no detectable changes in the solid state of the 
drugs.
The estimation of the printed drug amount for individualized dose 
adjustment showed high dependency on the volume and the stability of 
the jetted droplets. The drug content analysis of the printed dosage forms 
confirmed that the dosing accuracy of the inkjet printing was superior to the 
flexography. This was attributed to the fundamental differences in the ink 
transfer mechanisms between those two 2D printing methods. The flexible 
dosing of the pharmaceuticals was obtained with high precision by adjusting 
the resolution of the drop-on-demand inkjet printing or the physical size of 
the printed dosage forms. 
The non-destructive attenuated total reflectance Fourier transform 
infrared (ATR-FTIR) spectroscopy was found to be a good technique for 
the quantitative analysis of printed pharmaceuticals. The univariate analysis 
of the ATR-FTIR spectral data revealed a logarithmic correlation with the 
printed drug content. The Partial Least Squares regression models from the 
multivariate data analysis were obtained with an acceptable predictability 
regardless of the solid state of the printed drug. The results showed that 
spectroscopic methods have tremendous possibilities in the quality control of 
the printed dosage forms. 
The nanoparticulate systems exhibited an enhanced in vitro drug release 
due to the spatial distribution of the nanosuspensions on the substrates 
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that hindered the aggregation of the solid particles. The release profiles 
of the drugs from the surface of the non-porous reference substrate were 
comparable to the initial nanosuspensions, whereas the printed formulations 
on the edible substrates showed a slower release rate due to the penetration of 
the ink into the carrier matrices. 
The preparation of the combination DDS was successfully demonstrated 
by exploiting two different techniques for the incorporation of the active 
compounds. In the dual DDS, an ink solution with one drug was printed on 
the drug-loaded electrospun substrates containing another active compound. 
Both drugs exhibited an immediate drug release from the combination DDS. 
Thus, the use of drug-loaded fibrous substrates provided a good platform for 
the design of DDS with multiple active compounds. 
Currently the development of printed dosage forms is being thoroughly 
investigated to meet the needs of individualized drug therapy, and the design 
of these systems seems to be limited by one's own imagination. The printed 
dosage forms are highly feasibile for tailored drug therapy with various active 
compounds at high dosing uniformity and suitable drug release behavior. The 
presented research work provided a comprehensive insight into the design 
and production of personalized dosage forms by 2D printing technology. 
The analysis of the printed dosage forms improved the understanding of 
the crucial parameters in the development process as well as the in vitro 
performance and stability of the printed pharmaceuticals. 
More knowledge is continuously required on the formulation design 
aspects and the ink-substrate interactions that influence the solid state 
properties of the printed pharmaceuticals. In that context, the effect of 
printing parameters, for example the applied voltage and waveform in 
piezoelectric printing, and/or the printing temperature has not been 
systematically studied yet. The future prospects include the development of 
printed dosage forms with therapeutically relevant drug combinations and/
or with controlled drug release profiles. Further perspective is aimed at the 
analysis of the in vivo performance of the printed dosage forms, since more 
information is needed on the behavior of these systems in physiological 
conditions. In addition, the optimization of specific printing units with 
integrated or complementary quality control tools is required for the 
successful implementation of this method for the on-site manufacturing of 
personalized dosage forms.
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7. Sammanfattning (Summary in Swedish)
Design och utveckling av personifierade beredningsformer 
med hjälp av utskriftsteknologi
Utvecklingen av skräddarsydda beredningsformer erbjuder möjligheter 
till individuell läkemedelsterapi. Personifierade beredningsformer 
bidrar till säkrare vård och minskar risken för överdosering och 
biverkningar. Konventionella farmaceutiska preparat med förutbestämda 
dosstyrkor produceras vanligtvis i stor industriell skala. Däremot kunde 
beredningsformer för enskilda patienter framställas i små satser med 
specifika material, läkemedelsdoser och frisättningsprofiler. Därför undersöks 
alternativa tillverkningsmetoder, så som utskriftsteknologi, för framställning 
av skräddarsydda beredningsformer. Utskriftsteknologi är en flexibel 
framställningsmetod som även möjliggör tillverkning av farmaceutiska 
preparat med varierande dosstyrka vid vårdplatsen enligt patientens behov.
Syftet med denna avhandling var att undersöka ifall personifierade 
beredningsformer kunde tillverkas med hjälp av tvådimensionell 
(2D) utskriftsteknologi. Vid 2D-utskrift av läkemedel applicerades 
ett bläck innehållande läkemedel enligt ett fördefinierat mönster på 
bärarmaterialet. Den fasta beredningsformen uppnåddes efter torkning av 
bläcket på substratet. Doseringsnoggrannheten och reproducerbarheten 
av de bläckstråleutskrivna beredningsformerna möjliggjordes 
genom kontroll av antalet droppar och deras volym. Finjustering av 
beredningsformernas egenskaper och sammansättning tillät tillverkning 
av läkemedelsadministrationssystem (DDS) med kontrollerade 
frisättningsprofiler och/eller med flera olika aktiva farmaceutiska substanser.
I avhandlingen bevisades 2D-utskriftsteknologins mångsidighet 
genom design av utskrivna beredningsformer, med hjälp av antingen 
bläckstråleskrivare eller flexografisk tryckning på ätbara substrat med 
olika farmaceutiska bläck. De utskrivna beredningsformerna och deras 
komponenter analyserades för att fastställa avgörande aspekter av 
utvecklingsprocessen och förbättra kunskapen om utskrivna läkemedels 
fysikalisk-kemiska egenskaper, in vitro frisättningsprofil och stabilitet. 
Resultaten visade att utskrivbarheten av bläcket och de specifika 
utskrivningsparametrarna var beroende av de reologiska egenskaperna hos 
bläcket. Substratets förmåga att absorbera bläck, bläckets sammansättning 
och läkemedlens fysikalisk-kemiska egenskaper bidrog till den slutliga fasta 
fasen av de utskrivna läkemedlen. Analyserna visade att de slutliga fasta 
beredningsformerna innehöll den kristallina formen eller den molekylärt 
dispergerade fasen av den aktiva substansen. Den jämna distributionen 
av den kristallina nanosuspensionen på substraten bidrog till förbättrad 
in vitro läkemedelsfrisättning från de flexografiskt framställda fasta 
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nanopartikelssystemen.
Resultaten visade att en stabil bläckstråleutskrift var fördelaktigt med 
tanke på doseringsnoggrannheten. Den flexografiska tryckningsmetoden 
uppvisade mindre doseringsnoggrannhet av nanosuspensionerna främst 
på grund av hur bläcket överfördes till substratet. Doseringsflexibiliteten 
hos de utskrivna beredningsformerna uppnåddes genom bestämning av 
doseringsenhetens utskrivningsresolution eller den utskrivna ytan. Dämpad 
totalreflektion Fourierspektroskopi (ATR-FTIR) och multivariat dataanalys 
visade sig vara en användbar och icke-destruktiv metod för dosbestämning av 
de utskrivna läkemedlen.
I avhandlingen undersöktes även lämpligheten att använda elektrospunna 
fibrösa matriser som substrat vid framställning av de utskrivna 
beredningsformerna. Läkemedel inkorporerade i de elektrospunna 
fibrerna tillverkades med stabilisering av den amorfa fasen av det svårt 
vattenlösliga läkemedlet i de inre strukturerna av de elektrospunna fibrerna. 
Användningen av fibrösa substrat innehållande läkemedel presenterade 
ett nytt sätt att framställa DDS med två aktiva substanser. Detta system 
erhölls genom utskrift av ett läkemedel på elektrospunnet fibröst substrat 
innehållande ett annat läkemedel. Analyserna av de utvecklade kombinerade 
beredningsformerna visade att de i DDS ingående läkemedlen hade 
självständiga frisättningsprofiler. 
I avhandlingen presenteras en omfattande översikt över de huvudsakliga 
aspekterna för utveckling av personifierade beredningsformer med hjälp av 
2D-utskriftsteknologi. Forskningsresultaten förbättrar förståelsen av viktiga 
faktorer för finjustering och tillverkning av utskrivna beredningsformer, 
vidareutvecklar kvalitetskontrollaspekterna av utskriftsprocessen samt 
erbjuder insikter i väsentliga egenskaper hos de utskrivna läkemedlen.
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8. Kokkuvõte (Summary in Estonian)
Personaliseeritud ravimvormide väljatöötamine 
printimistehnoloogia abil
Sissejuhatus
Personaliseeritud meditsiin arvestab raviskeemi koostamisel patsiendi 
füsioloogiliste, ealiste ja käitumuslike eripäradega, mis mõjutavad ravimite 
farmakokineetikat ja -dünaamikat, raviainete toimet ja kõrvaltoimete 
esinemist (Cohen, 1999; Breitkreutz and Boos, 2007; European Medicines 
Agency, 2013). Lisaks võimaldab diagnostiliste testide ühildamine 
patsiendile orienteeritud ravimvormidega tiheda tagasiside süsteemi loomist 
(Alhnan et al., 2016; Sandler and Preis, 2016). Taolise kontseptsiooni ellu 
viimiseks on vajalik personaliseeritud ravimvormide väiksemahuline 
valmistamine vastavalt patsiendi vajadustele (Hamburg and Collins, 
2010). Tootmisprotsessid, mida kasutatakse tänapäeval konventsionaalsete 
ravimpreparaatide valmistamiseks, on tihtipeale liiga jäigad, mistõttu ei ole 
lihtne muuta raviplaani alusel raviaine sisaldust preparaatides. Sellepärast 
uuritakse alternatiivseid tootmistehnoloogiaid, mida saaks kasutada tootmaks 
ravimpreparaate, mille omadusi on võimalik modifitseerida vastavalt 
vajadusele. 
Ravimprintimine tähendab ravimpreparaatide või -toodete valmistamist 
printimise abil. Kahe- (2D) või kolmemõõtmeline (3D) printimine pakub 
mitmeid tehnoloogilisi võimalusi personaliseeritud meditsiinis. Viimaste 
aastakümnete jooksul on loodud erinevaid prinditud ravimkandursüsteeme 
(Sandler et al., 2011; Kolakovic et al., 2013; Alomari et al., 2015; Preis et al., 
2015; Scoutaris et al., 2016), meditsiiniseadmeid (Wu et al., 1996; Katstra 
et al., 2000; Tarcha et al., 2007; Shafiee and Atala, 2016) ning raviainet 
sisaldavaid funktsionaalseid katteid transdermaalsetele mikronõeladele 
(Boehm et al., 2014; Ross et al., 2015; Uddin et al., 2015) ja implantaatidele 
(Nganga et al., 2014). 
Uurimistöös keskenduti 2D printimistehnoloogiale, sh tindiprintimisele 
ja fleksograafiale, mis on oma resolutsiooni ja tootlikkuse poolest sobilikud 
personaliseeritud ravimvormide valmistamiseks. Tindiprintimine on 
kontaktivaba meetod, mille puhul prinditav lahus kantakse printerist 
vastavalt digitaalselt kujundatud mustrile kindlale kohale kandematerjalil 
ehk substraadil. Fleksograafia on kõrgtrüki eriliik, kus prinditava materjali 
trükkimiseks kasutatakse trükivorme rullrotatsioonmasinal. Erinevalt 
tindiprintimisest on fleksograafiliselt prinditud ravimvormi kvaliteedi 
tagamiseks vajalik piisav kokkupuude prinditava materjaliga kaetud 
trükivormi ja substraadi vahel (Kolakovic et al., 2013). 
Prinditud ravimvormide ülesehitus oleneb nende manustamisviisist. 
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Lisaks raviaine toime modifitseerimisel on võimalik muuta ravimvormide 
suurust, kuju ja organoleptilisi omadusi. Üldiselt koosneb prinditud süsteem 
kahest põhikomponendist: prinditav materjal ja substraat. Ravimprintimisel 
on prinditavaks materjaliks raviainet sisaldav lahus, (nano)suspensioon 
(Pardeike et al. 2011; Janßen et al., 2013) või bioloogiliselt aktiivset ainet 
sisaldav süsteem (Di Risio and Yan, 2007; Derby, 2008). Ravimvormides 
on substraatidena võimalik kasutada polümeerkilesid, söödavaid pabereid 
või muid bioloogiliselt ühilduvaid materjale. Üldiselt on eelistatud 
substraadid, mis on inertsed ja sobituvad kokku erinevate prinditavate 
materjalide ja raviainetega. Samas võimaldab nende funktsionaliseerimine 
mõjutada adhesioonivõimet, lagunemist või maitset. Lisaks saab kasutada 
polümeersetest nano- või mikrofiibritest koosnevate substraatide 
valmistamiseks elektrospinnimise meetodit (Greiner and Wendorff, 2007; 
Agarwal et al., 2008; Bhardwaj and Kundu, 2010). Seejuures on prinditava 
raviaine kogus määratletud raviaine kontsentratsiooni, prinditava pindala, 
kandematerjali imamisvõime ja printimiseks disainitud struktuuriga. 
Prinditud ravimite kvaliteedi tagavad prinditava materjali ja substraadi 
omadused, nende komponentide omavaheline sobivus ja printimissätted. 
Lahuste prinditavust on võimalik hinnata ühikuta Z-arvu alusel (Fromm, 
1984; McKinley and Renardy, 2011). Selle põhjal määravad lahuse viskoossus, 
pindpinevus ja tihedus ning nende muutumine printimisprotsessi jooksul 
tilga moodustumise ja väljutamise printerist (Barnes et al., 1989; Le, 
1998; Calvert, 2001, de Gans et al., 2004). Substraadi ja lahuse omadused 
(substraadi poorsus ja märgumine, lahuse absorptsioon ja tahkestumine) ning 
nende omavaheline sobivus mõjutavad prinditud süsteemi kuivamist (Calvert, 
2001; Derby, 2010; Määttänen et al., 2010). Need interaktsioonid mõjutavad 
ka ravimpreparaatides esineva raviaine tahket vormi (Sandler et al., 2011; Hsu 
et al., 2012; Raijada et al., 2013; Buanz et al., 2013). 
Ravimpreparaatide kvaliteedi tagamiseks tuleb analüüsida raviainete/
abiainete füsikokeemilisi omadusi kogu tootmisprotsessi erinevates etappides. 
Prinditud ravimvormide valmistamine vastavalt nõudlusele vähendab 
raviaine tahke vormi muutuste ja füsikokeemilise lagunemise esinemist 
(Raijada et al., 2013). Raviaine molekulaarsete omaduste ja sisalduse 
uurimiseks proovi kahjustamata kasutatakse eelkõige spektroskoopilisi ja 
röntgendifraktomeetrilisi meetodeid (Savolainen et al., 2006; Aaltonen et al., 
2008). Prinditud ravimkandursüsteemide analüüsimiseks on senini kasutatud 
näiteks Raman ja infrapunaspektroskoopiat, röntgendifraktomeetriat ning 
lähi-infrapuna hüperspektraalset pildianalüüsi (Melendez et al., 2008; Buanz 
et al., 2013; Vakili et al., 2014).
Uurimistöö keskendus 2D printimistehnoloogia abil personaliseeritud 
ravimvormide valmistamisele ja iseloomustamisele. Töös hinnati prinditud 
ravimvormide võimalikku rakendamist personaliseeritud ravimvormide 
valmistamisel ja analüüsiti prinditud raviainete füsikokeemilisi omadusi.
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Uurimistöö põhieesmärgid
Uurimistöö põhieesmärk oli välja selgitada 2D printimistehnoloogia 
rakendamisvõimalused personaliseeritud ravimvormide valmistamisel. 
Uurimistöö oli suunatud prinditud ravimvormide valmistamisele ja 
analüüsimisele ning arendusprotsessi eripärasuste kindlaks määramisele.
Uurimistöö spetsiifilised eesmärgid olid:
- valmistada tindi- ja fleksograafilises printimises kasutatavad 
farmatseutilised lahused, nanosuspensioonid ja kandesubstraadid;
- analüüsida prinditud ravimvormide füsikokeemilisi omadusi;
- hinnata tindiprintimise täpsust ja paindlikkust raviainete annustamisel;
- kasutada infrapunaspektroskoopiat prinditud raviainete 
kvantifitseerimiseks;
- analüüsida raviainete in vitro vabanemist fleksograafiliselt prinditud 
nano-osakestega süsteemidest;
- kujundada ja analüüsida kahte raviainet sisaldavat prinditud 
ravimkandursüsteemi.
Materjalid ja meetodid
Printimislahustes kasutatud mudelraviained olid veevaba kofeiin 
(CAF), loperamiidvesinikkloriid (LOP) ja lidokaiinvesinikkloriidi (LH) 
monohüdraat. Printimise baaslahus sisaldas lahustina puhastatud vett või 
etanooli (≥99,7%) ning solubiliseeriva ainena propüleenglükooli (PG). Vesi-
nanosuspensioonid fleksograafiliseks printimiseks valmistati vees halvasti 
lahustuva itrakonasooli (ITR) ja indometasiiniga (IND). 
Raviained prinditi kommertsiaalsetele kandesubstraatidele, laboratoorselt 
valmistatud hüdroksüpropüültselluloosi polümeerkiledele ja elektrospinnitud 
želatiinipõhistele fiibermattidele. Lisaks valmistati printimiseks piroksikaami 
(PRX) sisaldavad fiibermatid. Elektrospinnitud fiibermaatriksid ristseoti 
termilisel töötlemisel glükoosi juuresolekul. 
Prinditud ravimvormid valmistati piesoelektrilise tindiprintimise 
või fleksograafilise trükkimise abil. CAF ja LOP sisaldust prinditud 
ravimvormides varieeriti muutes printimisresolutsiooni või prinditavat 
pindala. Piesoelektriliselt prinditud LH sisaldavate ravimvormide stabiilsust 
uuriti 4 või 8 kuu vältel. 
CAF ja LOP sisaldavate printimislahuste prinditavust hinnati lahuste 
viskoossust ja pindpinevust mõõtes. Nanosuspensioonides määrati 
dünaamilise valguse hajuvuse meetodil tahkete osakeste suurus ja 
suurusjaotus. Elektrospinnitud fiibermattide mehhaanilise tugevuse 
hindamiseks viidi läbi läbistus- ja tõmbekatsed tekstuurianalüsaatoriga. 
Uurimistöös kasutati prinditud ravimvormide analüüsimiseks järgmisi 
meetodeid: skaneeriv elektronmikroskoopia, diferentsiaalne skaneeriv 
kalorimeetria, röntgendifraktomeetria ja nõrgendatud täieliku sisepeegelduse 
Fourier' teisendusega infrapunaspektroskoopia. Raviainete kvantitatiivses 
analüüsis rakendati ultraviolett-nähtav spektrofotomeetriat või kõrgefektiivset 
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vedelikkromatograafiat. Lisaks kasutati ühe- ja mitmemõõtmelist 
andmeanalüüsi määramaks CAF ja LOP sisaldust prinditud süsteemides 
infrapunaspektrite põhjal. 
ITR ja IND vabanemist prinditud ravimvormidest uuriti kohandatud 
in vitro dissolutsioonitestiga vastavalt fosfaatpuhvris (pH  5,0) või 0,1  M 
vesinikkloriidi lahuses (pH  1,2). LH ja PRX sisaldavatest ravimvormidest 
raviaine vabanemiskiiruse määramiseks simuleeritud süljelahuses 
(pH  6,8) (Marques et al., 2011) kasutati samuti modifitseeritud in vitro 
dissolutsioonitesti katsesüsteemi.
Tulemused ja arutelu
Mõõdetud viskoossuse, pindpinevuse ja tiheduse põhjal arvutatud Z-arv 
jäi CAF ja LOP sisaldavate printimislahuste puhul vahemikku 1–14, mis 
sobib piesoelektrilisel tindiprintimisel ühtlase tulemuse saavutamiseks. 
Sellele vaatamata erines nende lahuste pindpinevus märgatavalt, mis 
põhjustas tilga väljutamisel satelliit-tilkade (CAF lahus) või väljavenitatud 
tilkade (LOP lahus) moodustumist. Samas oli LH lahuse korral võimalik 
printimissätete muutmisega tagada pidev sfääriliste tilkade moodustumine. 
ITR ja IND nanosuspensioonides oli osakeste keskmine suurus vastavalt 
~420 ja ~700 nm. Kuulveskis valmistatud vesi-nanosuspensioonid sisaldasid 
stabilisaatorina mitteioonset surfaktanti Poloxamer 407 ja raviainet selle 
kristallilises vormis. Elektrospinnitud želatiinipõhised substraadid sisaldasid 
nanofiibreid, mille keskmine diameeter oli ~600  nm. Nende fiibermattide 
mehaaniline tugevus paranes kuni 5-kordselt termilise töötlemise järel. 
Fiibrite ristsidumine põhines mitte-ensümaatilisel Maillardi reaktsioonil 
glükoosi karbonüülrühma ja želatiini aminorühma vahel (Siimon et al., 2014, 
2015; Etxabide et al., 2015).
Printimislahuse ja substraadi vahelist füüsikalist koosmõju hinnati 
märgumisnurga mõõtmisega. Tulemused näitasid, et lahuste sorptsioon 
oli mõjutatud eelkõige pindpinevusest ning substraatide paksusest. 
Elektrospinnitud fiibrite lühiajaline hoiustamine ~70% õhuniiskuse juures 
muutis fiibermattide struktuuri kõvaks ja rabedaks, erinevalt termiliselt 
töödeldud fiibermattidest, mis säilitasid oma algse väljanägemise. 
Prinditud ravimvormide pinnamorfoloogia näitas, et veevaba CAF 
II vormi kristalliseerumise ulatus substraatidel olenes nende vedeliku 
imamisvõimest. Samas tahkestus LOP lahus uuritud substraatidel tilkadena, 
tagades raviaine molekulaarselt dispersse jaotumise. Printimisresolutsiooni 
suurendamisel oli näha LOP lahuse tahkestumist suuremate omavahel 
liitunud tilkadena. Glasuurlehtedel imendusid mõlemad lahused laias 
ulatuses materjali sisse, mistõttu substraadi pinnal oli tuvastatud raviaine 
kogus märgatavalt väiksem. Nanosuspensioonide fleksograafilisel trükkimisel 
oli prinditud pinna topograafia ebaühtlane, kuid sellele vaatamata ei 
täheldatud nano-osakeste ulatuslikku agregatsiooni. Nii ITR kui ka IND 
säilitasid printimise teel saadud tahketes nano-osakestega süsteemides 
Kokkuvõte
71
oma stabiilse kristallise vormi. Töödeldud fiibermatid ei lahustunud LH 
lahuse printimisel, kuid üksikud fiibrid pundusid ja kleepusid üksteise külge 
ning tasandasid ravimvormide prinditud ala. Sarnaselt LOP-ile oli ka LH 
prinditud ravimvormides molekulaarselt dispergeeritud. Tulemused viitasid, 
et viskoossuse tõstmiseks lisatud abiaine PG takistas prinditud raviainete 
kristalliseerumist. 
Tindiprinditud raviainete teoreetiline annus arvutati tilgamahu (pL), 
printimisresolutsiooni (dpi), printava pindala (cm2), prinditavate kihtide 
arvu ja lahuse kontsentratsiooni (mg/mL) põhjal. Raviainete annustamine 
tindiprintimisel valmistatud ravimvormides andis kvantitatiivses analüüsis 
tulemusi all 4%-lise suhtelise standardhälbega, mis oli märgatavalt täpsem 
võrreldes fleksograafiliselt trükitud ravimvormidega. Seejuures täheldati, 
et 8 kuu jooksul lagunes hüdrolüüsi tõttu ligikaudu 18% prinditud LH-st. 
Printimisresolutsiooni või prinditava pindala muutmisega sai reguleerida 
raviaine annust manustatavas ühikus. Prinditud pindala oli lineaarses 
korrelatsioonis prinditud raviaine kogusega. Seos raviaine koguse ja 
printimisresolutsiooni vahel oli määratud astmefunktsiooniga. 
Lisaks traditsioonilistele mõõtmismeetoditele analüüsiti CAF ja LOP 
kvantifitseerimiseks valmistatud prnditud ravimvormide infrapunaspektreid. 
Spektrite ühemõõtmeline analüüs, kus kasutati raviaine-spetsiifiliste 
neeldumismaksimumide intensiivsust või pindala, näitas lineaarset 
korrelatsiooni printimisresolutsiooniga ning logaritmilist seost raviaine 
kogusega. Selleks, et vähendada raviaine tahkest vormist, abiainetest ja/
või substraadist tingitud varieeruvust, kasutati spektrite mitmemõõtmelist 
analüüsi. Kvantifitseerimiseks koostati korrelatsioonikogumi põhjal osalise 
vähimruudu (PLS) regressiooni mudelid. Tänu madala hindamisvea ja hea 
ennustusvõimega mudelitele sai infrapunaspektrite põhjal määrata raviaine 
sisaldust katsekogumis olevates prinditud ravimvormides. 
Nanosuspensioonide valmistamine parandas raviainete in vitro 
lahustumiskiirust vesikeskkonnas. Fleksograafiliselt prinditud nano-
osakestega süsteemides sõltus raviaine vabanemine substraadist. 
Nanosuspensioonide inkorporeerumine poorsete riisipaberite struktuuri 
aeglustas raviaine vabanemist võrreldes plastkiledele prinditud 
ravimvormidega. Prinditud raviaine osakeste ruumiliselt ühtlane jaotumine 
substraadil takistas agregatsiooni ja soodustas raviaine lahustumiskiiruse 
paranemist. 
Kahte raviainet sisaldava ravimkandursüsteemi valmistamiseks 
kombineeriti raviainete lisamiseks kaks erinevat meetodit. Esmalt valmistati 
elektrospinnimise teel 6,5%  (m/m) PRX sisaldavad mikrofiibrid, mis 
sarnaselt raviaineta fiibermattidele ristseoti termilisel töötlemisel. Erinevate 
analüüsimeetoditega tuvastati, et elektrospinnitud mikrofiibrites oli PRX 
stabiliseeritud amorfses vormis, mis oli eelkõige tänu fiibrite struktuurilisele 
eripärale. PRX sisaldavaid fiibermatte kasutati substraatidena LH 
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vesilahuse printimisel. Lõpptulemusena saadi kahe raviainega prinditud 
ravimkandursüsteem, kus amorfset PRX sisaldava fiibersubstraadi pinnal oli 
LH molekulaarselt dispersses vormis. In vitro dissolutsioonitesti tingimustes 
vabanesid ravimkandursüsteemist mõlemad raviained koheselt üksteisest 
sõltumata.
Järeldused
Uurimistöö tulemused andsid põhjaliku ülevaate ravimvormide 
valmistamisest 2D printimistehnoloogia abil. Prinditud 
ravimkandursüsteemide analüüs parandas arusaamist tootmisprotsessi 
olulistest parameetritest, prinditud raviainete stabiilsusest ja in vitro 
käitumisest.  
Tindi- või fleksograafilise printimise jaoks valmistati vastavalt 
raviainet sisaldavad lahused või nanosuspensioonid. Selgitati, et 
valmistatud raviainelahuste viskoossus ja pindpinevus olid olulised 
parameetrid prinditavuse hindamisel. Prinditud ravimvormides kasutati 
kandesubstraatidena esmakordselt ka elektrospinnimise teel valmistatud 
želatiinipõhiseid fiibermatte.
Tahkete ravimvormide valmistamisel prinditi erinevad raviained 
biolagunevatele kandesubstraatidele. Raviainete füsikokeemilised omadused, 
printimislahuste koostis ja substraatide imamisvõime mõjutasid prinditud 
raviainete tahke aine vormi. Samas ei täheldatud fleksograafiliselt valmistatud 
nano-osakestega süsteemides raviainete tahke vormi muutusi.
Kontaktivaba tindiprintimine oli võrreldes fleksograafilise 
trükimeetodiga raviaine annustamisel täpsem. Tindiprintimisel võimaldas 
printimisresolutsiooni ja prinditava pindala süstemaatiline kohandamine 
reguleerida raviaine annust.
Nõrgendatud täieliku sisepeegelduse Fourier' teisendusega 
infrapunaspektroskoopia ja mitmemõõtmise andmeanalüüsi abil sai hinnata 
prinditud raviainete kvantitatiivset sisaldust proovi kahjustamata. Tulemused 
viitasid spektroskoopiliste meetodite mitmetele kasutamisvõimalustele 
prinditud ravimvormide kvaliteedikontrollis. 
Raviaine in vitro vabanemiskiirus tahkest nano-osakestega süsteemist 
paranes tänu osakeste ruumilisele jaotumisele, mis takistas nano-osakeste 
kuhjumist substraadi pinnal. Raviaine vabanemisprofiil mittepoorsele pinnale 
prinditud süsteemist oli võrdväärne algse nanosuspensiooniga. Samas raviaine 
inkorporeerumine biolaguneva kandematerjali maatriksisse aeglustas raviaine 
vabanemist.
Kahe erineva tehnoloogia kasutamise abil oli võimalik valmistada 
kombinatsioon-ravimkandursüsteem, kus raviainete vabanemine oli 
üksteisest sõltumatu. Valmistatud mudelsüsteem sisaldas LH, mis oli 
prinditud amorfset PRX sisaldavatele elektrospinnitud fiibermattidele. 
Seega saab luua kombinatsioon-ravimkandursüsteeme, kasutades raviainet 
sisaldavaid substraate.
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